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SUMMARY 
 State-of-the-art drug delivery currently focuses on delivery vehicle size, surface 
chemistry, and/or receptor interactions, all with the hope of improving drug accumulation 
within the tissue target. This work seeks to alter this paradigm by recognizing that tissue 
targets are not black boxes to which simply achieving accumulation is sufficient, but 
instead, complex microenvironments that house the cells that actually produce the 
function of the tissue and are the real targets of drug delivery. For example, while tissues 
critically involved in the regulation of immune processes, such as the lymphatics and 
lymph nodes, possess delivery barriers to getting drugs to their anatomical location, due 
to the complex spatial and temporal regulations of adaptive immune responses, these 
tissues, more importantly, possess delivery barriers to specific cells within them that must 
be overcome to achieve the desired immune response. The main innovation of this work, 
therefore, is that it addresses all drug delivery barriers, from site of injection to site of 
action, for the lymphatics and lymph nodes. This work has produced two novel 
nanoparticle-based delivery systems: one which proposes nitric oxide as a therapeutic for 
lymphatic-related therapies including direct delivery of nitric oxide to the lymphatics to 
regulate pumping function, and delivery of nitric oxide to lymph node-resident antigen 
presenting cells to increasing nanoparticle uptake as well as possibly promote tolerance; 
and the second which proposes a novel mechanism for the delivery of small molecules to 
deep lymph node cells for enhanced immune responses. Both of these systems while 
being nanoparticle-based, however, have engineered through either endogenous or 
synthetic chemistry the ability to release their small molecule payload, and thus are the 
first multi-stage lymphatic and lymph node drug delivery systems. 
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CHAPTER 1. Introduction 
 
1.1 Motivation 
The targeting of lymph nodes (LN), tissues where organized lymphocyte 
accumulation in the body occurs, has the potential to improve the treatment of a variety 
of pathologies, such as B and T cell malignancies as well as sentinel LN metastasis, and 
is the primary site of action for immunotherapeutic treatments.[1] In addition to 
facilitating LN targeting, delivery of therapeutic or imaging agents directly to the 
lymphatic endothelium is also of interest, since the lymphatics are involved in a wide 
variety of diseases either as the primary tissue of interest or as an accessory to the 
pathologies of other diseases.[2-5] Due to the integral role lymphatics play in tissue fluid 
regulation,[6, 7] lipid transport, and immune cell functions,[8-10] and the importance of 
the LN in generating adaptive immune responses,[9] there is thus, a clear need to develop 
a biomaterials approach to improving the efficacy of delivery of molecules within these 
deep tissues,[11] and to expound upon the rich cellular diversity within these tissues for 
eliciting more targeted immune responses. 
The therapeutic efficacy of administered drug, however, is restricted by several 
delivery barriers that reduce drug bioavailability and lifetime of action within the target 
site, with deleterious off-target effects and toxicities reducing the maximum tolerable 
dose.[11] Immunotherapy, which is of resurgent interest due to its potential to provide 
benefit in the treatment of a broad array of pathologies, primarily employs clinically 
approved small molecules or biologic agents, and thus requires strategies that enhance the 
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delivery of these drugs to tissues such as lymphoid tissues, and more specifically to the 
immune cells important in the initiation and regulation of immune response.[12] Hence, 
formulation approaches that improve immunotherapeutic drug bioactivity while 
minimizing off-target effects and toxicities are of high interest and include novel co-
formulation, targeting, and release schemes. Despite recent advances in drug formulation 
improving circulation times and targeting, however, efficacy is stymied by inadequate 
penetration into and retention within the lymphatics and LN, and there are currently no 
delivery strategies for providing cellular targeting that could dramatically improve drug 
efficacy.[11, 13] 
The overall goal of this work is, therefore, to address these technological needs by 
rationally designing a biomaterial platform capable of delivering therapeutics to immune 
cells within deep tissues such as the lymphatics and LN. To this end, such an approach 
would possess the following characteristics: 1) be in the critical size range for lymphatic 
uptake; 2) be able to deliver a wide variety of therapeutic agents; and 3) employ 
mechanisms to be able to modulate the targeting of specific lymphoid cells and tissues. 
We addressed this technological need by developing a lymphatic-draining nanoparticle 
(NP) system designed with either a physiological or engineered cargo release mechanism 
to deliver nitric oxide (NO) or immunotherapeutics, respectively, to LN-resident cells. 
Through the use of these multi-stage systems we have demonstrated that we can design 
for both improved tissue delivery as well as increased cellular access, and showed in vivo 




1.2 Specific Aims 
1.2.1 Specific Aim 1: S-nitrosated poly(propylene sulfide) NP for enhanced NO delivery 
to lymphatic tissues. 
The working hypothesis was that poly(propylene sulfide) NP are uniquely suited 
for creating a lymphatic/lymph node targeting NO-donor NP (SNO-NP) because they 
hold several advantages over existing NO donors: 1) by virtue of their unique size 
properties, the SNO-NP have significantly enhanced lymphatic uptake efficiency; 2) they 
are based on a chemistry that is physiologically compatible and bioavailable; and 3) they 
preserve the drug delivery benefits of micelle technology to enable precise and controlled 
delivery of encapsulated NO. Through the use of an ex vivo lymphatic-resident filarial 
worm model and an in vivo mouse lymphatic transport model, we were able to assess the 
biological activity and cellular distribution of these SNO-NP. We demonstrated the 
synthesis and modification of NP with NO in order to harness the physiological 
S-nitrosothiol chemistry for NO delivery and bioactivity. These SNO-NP stably 
encapsulated high levels of NO and facilitated its controlled release. In particular, we 
demonstrated that the bioactive form of released NO from SNO-NP, either NO2
-
 or SNO-
cysteine, depended on the ratio of free cysteine (CYS), a common endogenous low 
molecular weight thiol important in transnitrosation reactions, to SNO-NP. Furthermore, 
we demonstrated the cytotoxic activity of SNO-NP against lymphatic-resident B. malayi 
adult female filarial worms, for which there is no existing treatment. In vivo we showed 
that donation of NO from SNO-NP, which scaled in proportion to the total administered 
dose, enhanced LN accumulation by two orders of magnitude, compared to standard 
small molecule NO donor, without substantially reducing the lymphatic transport of NP 
or the viability and extent of NP uptake by LN-resident cells. Additionally, NO delivery 
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by SNO-NP was accompanied by low-to-negligible NO accumulation in systemic tissues 
with no apparent inflammation. These results suggest the utility and selectivity of SNO-
NP for the targeted treatment of NO-regulated diseases that afflict lymphatic tissues. 
1.2.2 Specific Aim 2: Multi-stage lymphatic-targeting NP delivery system augments 
lymphoma immunotherapy.  
The working hypothesis was that despite nanoformulations of an intermediate nanoscale 
size being ideal for lymphatic partitioning and LN accumulation after injection in the 
periphery, small molecules have increased potential to penetrate deeply within the LN 
cortex, therefore a controlled release strategy of co-formulated drug could be utilized to 
optimally target LN-resident cells via enhanced drug penetration. By conjugating our 
drug cargo to our lymphatic-targeting NP with oxanorbornadiene (OND) linkers, which 
undergo retro-Diels Alder fragmentation to release cargo with predefined half-lives, we 
demonstrated a versatile lymphatic-targeting NP system that was able to precisely tune 
the release profile of conjugated cargo within the lymphatic tissues. Through the use of in 
vivo lymphatic-transport and mouse tumor models we were able to assess the 
improvement in LN-resident cell targeting and immunotherapeutic response elicited by 
releasing small molecule cargo from lymphatic-draining NP. Using confocal imaging and 
flow cytometry we showed increased accumulation of released cargo and access to deep 
LN-resident cells. We were able to conjugate the TLR9 ligand CpG through our OND 
linkage to lymphatic-draining NP and demonstrated that these OND-CpG-NP 
dramatically altered the abundance and type of lymphocytes within the treated LN, 
producing a large increase in total lymphocytes and a greater maturation of resident 
antigen presenting cells (APCs). We further demonstrated that this delivery strategy 
afforded a substantial immunotherapeutic response shown by a dramatic reduction in LN 
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tumor size compared to other CpG delivery strategies, and a slowing of primary tumor 
growth. These results suggest the utility of the multi-stage OND-NP approach for the 
delivery of immunotherapeutics to LN-resident cells for the treatment of LN and primary 
tumors. 
1.3 Significance 
The work presented herein provides innovation in carrier design by improving the 
penetration of delivered agents deeply to within healthy and diseased tissues, as well as to 
tissue targets of emerging interest for their diagnostic and therapeutic utility – lymphatic 
vessels and the LN to which they drain. First, this work is important because it identifies 
NO as a therapeutic of particular interest for the treatment of lymphatic-related diseases, 
and has resulted in a novel NP-based delivery system that is able to enhance the delivery 
of NO to lymphatics and LN-resident cells; something that to our knowledge no other NP 
system or NO donor described to date can accomplish. Second, this work has refocused 
LN drug delivery to the cells within the LN instead of the tissue itself through the use of a 
multi-stage NP-based delivery system; something that to our knowledge has never been 
attempted for LN drug delivery. Overall, the significance of this work is the idea that 
accumulation within tissues such as the lymphatics and LNs is not a sufficient metric, 
instead, drug delivery design should take into account the spatial, temporal, and cellular 
regulation of the processes within the tissue targets that are trying to be achieved. 
Specific Aim 1. Diseases involving lymphatic tissues range from infectious and 
cardiovascular diseases to cancer and are estimated to afflict more than 40 million people 
worldwide. NO is a therapeutic implicated for the treatment of these diseases, however 
existing technologies available for NO therapy provide poor bioactivity within lymphatic 
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tissues. Our platform, SNO-NP, provides a solution to this significant technology gap by 
enabling facile delivery of NO to lymphatic tissues through an innovative NP formulation 
that encapsulates high levels of NO for its controlled release. Advantages of this 
technology for therapeutic applications in lymphatic tissue targeting include: a >100-fold 
increase in drug exposure in LN relative to small molecule NO donors to dramatically 
improve drug bioactivity; improved lymphatic tissue targeting to facilitate dose sparing 
and reduction of off-target side effects with minimal systemic and local inflammation; 
encapsulation of high per NP levels of NO, far surpassing those of existing NO donors; 
and biological activity of delivered NO including cytotoxicity against lymphatic-resident 
filarial worms. Furthermore, the ease of NP synthesis and NO loading, formulation 
stability, and composition make this technology highly amenable for therapeutic use. 
Specific Aim 2. Since LN are bathed in lymph drained from the periphery in a steady state 
fashion, design principles optimizing drug targeting for penetration through the 
interstitium and lymphatics to reach lymph using more conventional and less intrusive 
drug administration techniques, such as subcutaneous injection, are attractive for LN 
delivery. However, within the LN, solutes and particulates are filtered based on size, with 
smaller molecules penetrating more deeply into LN cortex than large particulates by 
virtue of uptake within LN conduits. Drug and macromolecular formulation therefore 
have the potential to play a significant role in regulating the distribution within the LN as 
a function of macromolecular size. To achieve localized delivery to LN-resident cells for 
immunotherapeutic responses, we have created a NP system that combines lymphatic-
targeting NP with time-released cargo linker optimized to increase accumulation and 
access to deep LN-resident cells, as well as improve immunotherapeutic responses 
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against LN and primary tumors. Advantages of this system include: a >100-fold increase 
in T and B cell targeting relative to conventional drug delivery; improved 
immunotherapeutic efficacy requiring lower doses of potent adjuvants with minimal 
potential for systemic off-target effects; multi-valency that allows for unique co-
formulation delivery; and a tunable release mechanism for altering cargo release profiles 
that has the potential to tune the cell types targeted within the LN. 
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CHAPTER 2. Background and Literature Review 
 
2.1 Introduction 
Drug efficacy after administration is restricted by its capacity to appreciably 
accumulate at the desired site of action at bioactive doses in order to mediate its 
effect(s).[11] The concept of drug targeting to enhance therapeutic benefit and minimize 
toxicities largely brings to mind the directed retention of drugs or imaging agents at and 
within cells and tissues of interest using affinity-based molecular interactions or, in the 
case of solid tumors, exploiting the leaky vasculature to facilitate their preferential 
accumulation. Hence, as in these situations, formulation approaches that improve 
lymphatic and LN drug bioactivity while minimizing systemic delivery are of high 
interest.[13] This background will discuss the relevant concepts pertinent to drug delivery 
to the lymphatics and LN, how formulation design and delivery schemes have facilitated 
advances in effective targeting and improved immunological outcomes for a variety of 
lymphatic/LN-related therapeutic purposes, explore novel treatment strategies for 
lymphatic/LN-related diseases, and discuss what challenges and opportunities remain. 
2.2 Drug Delivery for Lymphatics 
2.2.1 Lymphatic physiology 
Within the interstitium, which constitutes the extracellular space, solutes, matrix, 
and space between cells, exchange of solutes between the capillary plexus and the cells 
occurs. Due to differences in oncotic pressure between the arterial and venous sides of 
the capillary plexus as a result of permanent protein extravasation, not all of the fluid 
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makes its way back to the venous side, resulting in a putative net loss of up to 10% of 
circulation volume.[6] This volume loss would result in fluid accumulation if not for the 
lymphatic system, which drains the excess fluid and returns it to the circulation. Unlike 
the circulatory system, which contains a central pump, the lymphatics operate on a more 
local level. Within the interstitium, fluid uptake and transport by the initial lymphatics is 
thought to be driven by expansion and compression of the initial lymphatics, with 
expansion resulting in percolation of the interstitial fluid through the endothelial 
microvalves, resulting in filling of the initial lymphatics, which then get compressed by 
the surrounding tissue, sending the lymph out in the direction of the large collecting 
lymphatics.[14] The initial lymphatics are blind-ended and composed of non-fenestrated 
overlapped endothelial cells with anchoring filaments to the surrounding extracellular 
matrix in order to provide mechanical support against the low pressure inside the initial 
lymphatic vessel lumen.[15] Because of the relatively large fluid reabsorption rate 
difference between the vascular capillaries and the lymphatic, only a certain size range of 
molecules is preferentially taken up by the lymphatics,[16] which has major ramifications 
on drug formulation and delivery to the lymphatics following intradermal injection and 
will be discussed in more detail later.[11] Following initial lymphatic uptake the 
interstitial fluid moves to larger collecting lymphatics where it is termed lymph. Within 
the collecting lymphatic vessels, the lymph is propelled by a synchronized movement of 
lymphatic vessel compartments called lymphangions, which contain one-way valves to 
propel the lymph in a unidirectional manner. Surrounding the lymphatic vessels are a 
series of lymphatic smooth muscle cells which contract autonomically, squeezing the 
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lymphangions and propelling the lymph through the vessels, and eventually through the 
LN before returning the collected fluid to circulation.[6]  
While the main function of the lymphatics is the transport of interstitial fluid from 
the extracellular space to the circulation, the lymphatics are also involved in other 
important processes including facilitating immune cell homing and immune responses 
due to their distribution of fluid to the LN.[17] However, stagnation of lymph flow has 
been shown to disrupt these processes, making lymphatic pumping of lymph one of the 
lymphatics’ most critical functions.[7] Furthermore, the loss of pumping function can 
lead to pathologies such as edema, characterized by accumulation of fluid within the 
interstitial space. Consequently, the restoration of pumping function is an important 
aspect of lymphatic therapy relevant to many pathologies including myocardial 
infarction[18] and parasitic infection,[19] where expansion of the accumulating fluid 
causes damage to the surrounding tissue. 
2.2.2 Lymphatic diseases and current treatments 
Due to the integral role the lymphatics play in tissue fluid regulation,[6] lipid 
transport,[7] and immune cell functions,[8] the lymphatics are involved in a wide variety 
of diseases either as the primary tissue of interest, such as with lymphedema[2] or 
lymphatic filariasis,[3] or as an accessory to the pathologies of other diseases, such as 
with myocardial infarction[4, 5] and cancer.[10] The combined effect of all diseases in 
which the lymphatics are directly affected is staggering at an estimated 40M 
worldwide.[20, 21] Despite the high prevalence of lymphatic-associated diseases, 
treatment methods, especially for diseases where the lymphatics are the primary tissue of 
interest, remain stagnated or in some cases non-existent. As one example, the current 
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gold standard for the treatment of lymphatic filariasis, an infection of the lymphatics by 
parasitic worms, is the use of antibiotic cocktails that are administered systemically and 
do not result in appreciable drug accumulation within the lymphatics where the worms 
reside.[3] Moreover, lymphedema, one of the resulting diseases of lymphatic filariasis 
and sentinel LN removal following breast tumor resection, only employs a combination 
of compression and physical therapy.[22] For diseases where the lymphatics are not the 
primary target but are critically involved in the disease pathology or may be useful 
therapeutically, there exist few approved treatments that are specifically formulated to 
target the lymphatics, producing a range of undesired consequences from increased 
toxicity as a result of higher dosing to inefficient immune responses such as inhibited 
antigen uptake.[13] Thus, there is a clear need to develop effective therapies that 
specifically target the lymphatics and restore lymphatic function.  
2.2.3 Role of NO in lymphatic function 
NO is an extremely promiscuous biological molecule that takes part in a variety of 
physiological processes ranging from vasodilation, to neural signaling, to immune cell 
cytotoxic defenses. This small, semi-hydrophobic nonelectrolyte diffuses rapidly, 
accumulating preferentially in the lipid phases of cells.[23] Similar to blood vessel 
physiology, the vessels of the lymphatics are sensitive to shear stress and dilate 
accordingly to compensate for changes in lymph flow.[24, 25] NO is the signaling 
molecule responsible for facilitating this dilation.[26, 27] Under increased shear rates 
membrane-bound inducible nitric oxide synthase (iNOS) becomes activated and produces 
NO,[28] which can diffuse both apically towards the vessel lumen, or basally toward the 
underlying smooth muscle cells.[29] Once in the smooth muscle cell NO interacts with 
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cyclic guanosine monophosphate (cGMP) initiating a process that results in the 
sequestration of calcium, depriving the muscle cell of the ability to contract, and thus 
allowing the vessel to dilate.[30] However, the lymphatics are very sensitive to NO 
concentration[31] with several lymphatic-related disease symptoms/causes being 
alterations in lymphatic pumping function including lymphedema, which has been known 
to have aberrant NO concentrations.[32] Therefore, the putative therapeutic solution to 
restoring lymphatic pumping function in these diseases is to restore the signaling levels 
of NO to overcome whatever disease-induced adulteration of NO signaling has occurred. 
2.2.4 Clinical therapies for NO modulation 
Because of the important role that NO plays in multiple physiological processes, 
including neurotransmission,[33] vascular regulation,[34] immune response,[35] and 
cytotoxicity,[36] there have been many attempts at modulating NO for therapeutic 
purposes. For example, NO delivered in the form of nitrate is used to control pain from 
angina, a disease affecting 9 million people in the US with 500,000 new cases every year, 
and has been found to annually cost the healthcare system around $1.9 billion.[37] NO 
has also been investigated in several clinical trials for use with other cardiovascular 
treatments to control blood pressure in adults with prehypertension,[38, 39] which affects 
25-50% of adults worldwide,[40] and to improve the function of the heart following heart 
transplant or left ventricular assist device placement.[41] For pulmonary diseases NO is 
inhaled in its gaseous form, and is the current standard of care for persistent pulmonary 
hypertension in newborns, which affects 1.9 per 1000 live births.[42] NO has also been 
explored for the treatment of various cancers, including lymphoma where a variety of NO 
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donors have been shown to be chemosensitizers[43-45] as well as exhibit direct 
cytotoxicity.[45-49] 
2.2.5 Molecular carriers of nitric oxide: NO donors 
NO donors are molecular carriers of NO. While much research has gone into NO 
donors for therapeutic potential, only two types of NO donor are used clinically: organic 
nitrates and diazeniumdiolates (NONOates).[50] Despite the exclusiveness of these two 
types of NO donors, there exists other promising NO donor candidates, including the 
endogenous S-nitrosothiols. Endogenous S-nitrosothiols (R-SNO), which include S-
nitrosocysteine, S-nitroso-albumin, and S-nitrosoglutathione (GSNO) represent a major 
class of NO-nucleophile adducts that facilitate NO’s transport in vivo.[51-53] R-SNO are 
formed on free thiols either through reactions with nitrosating agents[54] or by 
transnitrosation (i.e., by transfer of NO from other nitrosothiols),[55, 56] giving R-SNO 
the ability to be formed under a wide range of (patho)physiological conditions.[57] 
Therefore, R-SNO represent an attractive and physiological NO chemistry that has been 
exploited to harness both native NO signalling and transport activity in biological 
systems.[50] 
2.2.6 Lymphatic-targeting drug delivery strategies 
Despite the versatility of NO as a potential therapeutic in a broad array of 
pathologies, several challenges exist with utilizing NO for lymphatic-related therapy. 
First, NO participates in many interrelated physiological processes that each have 
different requirements for NO signalling.[29, 58, 59] In some cases depletion or 
attenuation of NO signalling may produce negative effects such as in vascular 
regulation,[60] whereas in the case of inflammatory responses overproduction of NO can 
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lead to loss of lymphatic function.[31] Consequently, a lymphatic-targeted NO-based 
therapy would need to be tightly controllable, since NO levels vary significantly across 
physiological processes, pathologies, and locations.[24, 25, 28, 29, 61] Combined with 
the extremely short half-life[62, 63] of NO requiring it to mediate its action near its 
synthesis source,[62] targeted NO donation remains highly difficult. 
The second challenge to delivering NO, especially in the context of lymphatic-
related therapies, is the result of lymphatic delivery barriers.[9, 11] Due to the physiology 
of the lymphatic system, typical intravenously administered molecules do not result in 
appreciable delivery to lymphatics, with a considerable portion of administered agent 
accumulating instead in the lung, kidney, and liver. As a result, direct injection 
techniques are typically utilized for lymphatic targeted delivery strategies.[10, 64] 
Predominantly macromolecular size aspects of the connective tissue physiology govern 
the feasibility of lymphatic and lymph delivery (Figure 2.1) despite the influence of 
interstitial flow on transporting injected agent into the draining lymphatics. Since non-
fenestrated blood capillaries are permeable to molecular species less than 5 nm in 
hydrodynamic diameter,[65] they are rapidly cleared after injection,[66] reducing their 
potential for lymphatic exposure. Conversely, since the pore size of the extracellular 
matrix (ECM) limits the movement of macromolecular species through the interstitium, 
infused nanoformulations ~100 nm or larger become entrapped[67] and are too poorly 
suited to lymphatic-targeted drug delivery applications (Figure 2.1). Therefore species 
roughly 5 nm or larger, but smaller than 100 nm, are largely impermeable to the blood 
capillaries within healthy tissues[65] and can only be efficiently cleared by lymphatic 
drainage mechanisms. Lymphatic targeting is therefore optimized by agents or 
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formulations roughly tens of nanometers in hydrodynamic diameter, including the 
synthetic formulations ~30 nm Pluronic-stabilized poly(propylene sulfide) NP[67] used 
in this work.  
 
Figure 2.1: Within the interstitium under the influence of slow interstitial fluid flow, 
macromolecular transport is restricted by the ECM. (i) Large (>70 kDa) but not 
small molecular species become entrapped by the gel-like ECM.[64] At similar 
hydrodynamic radii, penetration through the ECM is increased by (ii) high particle 
aspect ratios, which correspond to a smaller Stokes radius along one carrier 
dimension,[68] and (iii) flexibility of the macromolecular assembly, such as that 
exhibited by biopolymers.[11, 67] 
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In addition to achieving lymph accumulation via transluminal transport, and 
perhaps most importantly for NO therapy, delivery of agents directly to the lymphatic 
endothelium is of interest. NO is known to cause dilatory responses in lymphatic vessels, 
despite the fact that areas of increased NO concentration such as the lymphatic valves[24, 
28] have been found, there is no quantitative understanding about how NO signalling 
levels impact lymphatic pumping function. This has important ramifications for 
lymphatic targeting since physiological NO levels are required to maintain basal 
lymphatic functionality,[26] whereas infra[27] and supra-physiological[31] levels of NO, 
as are seen in many disease states, impede lymphatic contractility and pump function. 
2.2.7 Drug delivery vehicles for NO modulation 
Given the importance of the lymphatics as a tissue target and the pronounced effect 
NO has on lymphatic function, modulation of NO within lymphatics offers a promising 
means of restoring endogenous NO signalling and alleviating lymphatic deficiencies that 
contribute to many diseases. Drug delivery systems offer a promising solution; they 
encompass a wide variety of carriers composed primarily of lipids and/or polymers, and 
serve the purpose of altering the pharmacokinetics and biodistribution of their associated 
small molecule drug (Figure 2.2, upper left). There has been expansive research into 
novel formulations of drug delivery vehicles including: synthetic micelles, dendrimers, 
NP, microspheres, liposomes, etc.[66, 69, 70] While each carrier has its advantages and 
has found use for specific applications and/or targets, drug delivery vehicles in general all 
work by increasing the molecular weight of the delivered drug;[71] this results in a 
reduction of the clearance rate by the reticuloendothelial system and an increase in 
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circulation time. In order to utilize NO-modulation for lymphatic therapy, formulation of 
NO donors into a lymphatic specific carrier is required. 
 
Figure 2.2: Schematic diagram of nanoformulations that improve 
immunotherapeutic drug efficacy. Top left: nanoformulations that increase the 
effective hydrodynamic size of drugs improve their circulation times by resisting 
glomerular filtration, enhance tumor accumulation by the enhanced permeability 
and retention effect, and may promote lymphatic uptake from the interstitium. Top 
right: co-delivery via co-formulation improves the synergistic signaling activity of 
multiple immunotherapeutic agents, for example, antigen and adjuvant in vaccine 
applications. Bottom left: PEGylation increases the effective hydrodynamic size and 
stealth properties of nanoformulations to increase drug half-life after infusion. 
Bottom right: ligand targeting can increase uptake by immune cells in a density-
dependent fashion. PEG poly(ethylene glycol).[71] 
While there have been several examples of reformulation of NO donors to achieve 
improved pharmacokinetics and biodistribution including improving circulation time 
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through polyethylene glycol (PEG) conjugation[72] and NO bioactivity through multi-
valency,[73] there have been no attempts to create a NO donor specifically for targeting 
lymphatics.[74] Several examples exist of larger molecular weight NO donors including a 
64-valency R-SNO dendrimer donor[73] and NO-containing NP;[75-79] however, all of 
these approaches remain insufficient for NO-modulation within the lymphatics because 
such formulations are non-optimized for lymphatic uptake.[74] 
2.3 LN drug delivery strategies 
2.3.1 LN physiology and its role in adaptive immune responses 
LN are lymphoid tissues comprised primarily of immune cells with a supporting 
stroma whose primary function is to facilitate contact between lymphocytes in the 
mounting of adaptive immune reactions. They are thus central targets in immunotherapy 
applications, such as vaccines[80] or immune suppressive regimens.[81] Most primary 
adaptive immune responses against peripheral pathogens are initiated in the T cell area of 
the LN, therefore how the mechanisms involved in the antigen presentation between 
dendritic cells (DCs) and T cells depend on LN structure are important to LN drug 
delivery. Antigen presentation to T cells is thought to occur via two distinct mechanisms 
(Figure 2.3). The first pathway is well characterized and involves the migration of 
peripheral DCs that acquired peripheral antigen and then trafficked through the afferent 
lymphatics into the T cell areas of the draining LN (Figure 2.3).[82] The second pathway 
of antigen presentation is most often the target of drug delivery strategies and functions 
independently of the cellular-mediated pathway. This second pathway involves the 
acquisition, presentation, and cross-presentation of soluble antigen that transports 
passively from the periphery to the LN-resident DCs that then initiate T cell activation 
 19 
(Figure 2.3).[82] These putative distinct “waves” of antigen presentation – cellular 
trafficking vs. soluble draining – are thought to induce functionally different T cell 
responses due to both their differences in timing as well as potency of DC activation.[82] 
In fact, regarding CD4 T cell responses, peptide:MHC II presentation by LN-resident 
DCs, especially lymphatic-sinus lining DCs, was shown to rapidly and sufficiently induce 
many aspects of T cell activation including IL-2 receptor expression and proliferation, 
indicating that soluble antigen transport to the LN is an important step in T cell 
activation, despite the requirement for the arrival of more potent antigen presenting 
peripheral DCs in order to induce a longer lasting and more potent CD4 T cell 
response.[82, 83] Likewise, for CD8 T cell responses, it has been shown that conduit-
lining DCs can directly sample antigen from the conduits, resulting in earlier T cell 
activation independent of peripheral DCs migrating several days later. Therefore, the 
mechanism by which soluble transport of peripheral antigen reaches and distributes to the 




Figure 2.3: Principles of LN targeting including the major transport barriers of the 
interstitium and the LN subcapsular sinus. Antigen presenting cells such as DC take 
up large particles (particle-carrying DC) and actively migrate to LN. Synthetic 
carriers such as NP 10–100 nm in diameter (optimum for penetration of the 
interstitial extracellular matrix) as well as protein antigens are carried from the 
interstitium by interstitial and lymphatic flows to draining LN. Lymph-borne 
solutes are distributed within LN in a size dependent fashion. For example, large 
protein antigens (Lrg Ag) are taken up by subcapsular macrophages (SCS MF) and 
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transferred to follicular DC either directly or as mediated by B cells. Small protein 
antigens (Sml Ag), however, are efficiently taken up by follicular conduits and 
directly transported to B cell follicles or the T cell cortex. Thick arrows, direction of 
flow. Thin arrows, direction of antigen transfer to and between LN-resident 
cells.[11] 
For the last two decades the role of the reticular LN network in the distribution of 
antigen to deep LN cells including DCs and B cells has been explored extensively. 
Canonical studies demonstrated that soluble molecules within the lymph do not move 
freely through the cortical parenchyma of the LN, rather, they primarily are found within 
the reticular network’s conduit system (Figure 2.3, insert). The reticular network, which 
functions as the LN’s infrastructure, is a mesh of collagenous fibers that connects the 
floor of the subcapsular sinus to high endothelial venules (HEVs) through the 
extracellular matrix of the sinus endothelium and the basement membranes of the 
HEVs.[84, 85] Within this meshwork, “conduits” of the reticular network are formed. 
Composed of highly specialized extracellular matrix, these conduits consist of a central 
core of interstitial matrix molecules, collagen types I and III, which is surrounded by a 
basement membrane-like structure that is then ensheathed by a layer of fibroblastic 
reticular cells (FRC). The uniqueness of the conduit comes from its basement membrane, 
which does not separate two cellular compartments as is the norm, but rather surrounds 
an acellular lumen through which soluble molecules are transported. Additionally, an 
extracellular matrix layer containing fibrillin-1 and fibrillin-2 exists between the collagen 
core and the basement membrane, and has been shown to be important in facilitating DC-
mediated contact involved in sampling conduit-resident antigen.[84]  
This reticular network has been shown to restrict access of lymph-borne material 
to the cortical parenchyma which is important in not only preserving the naïve state of the 
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lymphocyte microenvironments, but also in protecting from a wide variety of 
immunogenic molecules that would adversely influence an immune response occurring 
within the cortex, such as microbes and their soluble products during microbial 
infections.[85] The efficiency of this barrier has been extensively shown to depend on the 
size of the lymph-borne molecules (Figure 2.3) with high molecular weight (MW) tracers 
all but virtually excluded from conduit and cortex access by the subcapsular sinus. The 
fate of these high MW tracers as well as large particulates has been shown to be 
scavenging by either the lymphatic-sinus processes of sinus-lining DCs or CD169+ 
subcapsular sinus macrophages (Figure 2.3), both of which resulting in rapid CD4 T cell 
responses, although CD169+ subcapsular sinus macrophages have been shown to proceed 
through B cell transfer of antigen opposed to DC presentation.[83, 86-88] Conversely, 
low MW tracers experience graduated but not absolute exclusion, with molecules under 
70 kDa having access to the conduits.[84, 85] However, permeation of these low MW 
molecules from the conduits to the lymphocytes within the paracortex is mostly 
restricted, indicating that for immune challenges with limited antigen concentration this 
might be a significant barrier, but with larger concentrations direct lymphocyte access 
could be possible on a physiologically significant scale. Interestingly, there exists a limit 
to the protection of the cortical parenchyma by the reticular barrier as very small 
molecules such as tritiated uridine (∼350 daltons)[89] and acridine orange (302 
daltons)[85, 90] have free movement of throughout the cortex. In terms of how this 
conduit system affects the delivery of antigen to LN-resident DCs and their subsequent 
presentation to T cells, it has been shown that resident DC are in close contact with the 
conduits and have access to their contents through extensions of their processes into the 
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conduit lumen (Figure 2.3).[84]  These DCs are immotile while on the conduits, but once 
they have taken up their antigen they no longer interact with the fibrin structural 
backbone of the conduit extracellular matrix core, and become more motile and migrate 
to the T cell paracortex to present antigen.[84, 88] 
2.3.2 LN diseases and current treatment 
The LN are the primary organs where adaptive immune responses of the body 
occur, and as such their health is important to maintaining a functioning immune 
system.[1] The primary disease associated with LN is the presence of cancer, which can 
occur in LN by one of two mechanisms: it can originate in the LN, in which case its 
referred to as lymphoma, or it can spread there as a result of metastasis from another 
primary tumor site.[91, 92] In America, more than 15.5 million people have a history of 
cancer, and it is estimated that in 2018 there will be around 1.7 million new cancer cases 
diagnosed.[93] This tremendous number of new and total cancer cases will result in over 
600,000 Americans dying in 2018, or more than 1600 deaths per day, making cancer the 
second most common cause of death in the US behind heart disease.[93] Of all of these 
deaths, more than 90% will occur due to metastasis, with the tumor-draining LN 
commonly being the first organ of metastasis for many types of cancer.[92] This function 
of LN has important clinical promises for diagnostic utility in staging disease as well as 
mounting anti-cancer immune responses due to the presence of tumor-derived antigen 
within these sentinel LN. Sentinel LN are therefore critically involved in directing anti-
tumor immune response and suppression,[94, 95] and consequently, both 
chemotherapeutic[96] and immunotherapeutic[10] interventions targeting these LN have 
been explored. Lymphomas, on the other hand, originate in the LN and result in over 
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80,000 diagnoses and 20,000 deaths per year.[93] Regardless of the etiology, cancer in 
the LN presents interesting opportunities for treatment including immunotherapy, which 
is a type of treatment that uses the body’s own immune system to treat the cancer and 
includes: checkpoint inhibitors, cancer vaccines, and non-specific cancer 
immunotherapies and adjuvants.[97]  
Despite these advanced treatments, there still remain great challenges with 
improving immunotherapeutic outcomes. Based on the mechanism of adaptive immune 
response whereby an APC will encounter cancer antigen, either exogenously 
administered or endogenously encountered from the draining tumor site, and activate 
cytotoxic T cells with the cognate T cell receptor for the antigen, many cancer vaccines 
or adjuvants rely on cell mediated trafficking to the LN in order to elicit an immune 
response.[71] However, recently taking advantage of the second mechanism of antigen 
delivery to LN has become popular with myriad drug delivery systems designed to 
improve upon the efficiency of antigen transport. Due to the structure of the lymphatics 
and the partitioning of solutes within the LN, both of which are favor opposing size 
scales of molecules, there however, remains a significant technological gap in exploiting 
passive diffusion of administered therapeutics, which occur on a more rapid time scale 
than cellular mediated delivery, in order to achieve an immune response.[11] 
2.3.3 LN targeting drug delivery strategies 
Direct injection of LN has shown promise for immunotherapy,[98] but is too 
laborious and impractical for most drug delivery scenarios. Since LN are bathed in lymph 
drained by afferent lymphatics from the periphery in a steady state fashion, drug delivery 
design principles discussed previously optimizing for lymphatic uptake will be applicable 
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for LN delivery (Figure 2.2 and 2.3). As with lymphatic targeting, after direct injection in 
the periphery, interstitial flow follows a one-way path toward the lymphatic capillary and 
subsequently to the draining LN, resulting in a highly facile yet robust LN targeting. 
Design wise, the formulation must mainly be small enough so as to not be entrapped by 
the tissue interstitium, yet large enough not to be cleared into the circulation after 
injection, corresponding to roughly 10-100 nm in hydrodynamic radius, and ideally 20-40 
nm.[66, 67, 99, 100] However, this size dynamic changes within the LN as the structure 
of the LN controls access of antigen to the cells, as solutes and particulates undergo size-
based distribution within the LN.[8, 85, 101] The complex filtering taking place in the 
LN plays a critical role in the rate, extent, and distribution of agent accumulation that 
may influence drug efficacy, required dose, associated toxicities, and cellular access. For 
example, large soluble antigen such as virus-like particles and exosomes are excluded by 
the subcapsular sinus, which represents a barrier to deep access to the LN parenchyma 
where cortical T cells reside.[8, 85] While CD169 positive macrophages, which line the 
subcapsular sinus, are capable of scavenging these large particulate antigens and 
presenting them to active B cells, this results instead in a putative mechanism for rapid 
humoral responses.[86-88] Small molecules < 70 kDa penetrate more deeply into LN as 
the result of enhanced shunting through LN conduits relative to larger molecules.[84] 
These conduits pass near centralized LN structures where T cells reside,[8, 84] and are 
lined with follicular DCs that are able to scavenge antigen within the conduits and present 
it directly to T cells.[84] This mechanism to achieve T cell responses is thought to occur 
on a much quicker time scale than cellular-mediated delivery of antigen from the 
periphery.[84] 
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While the advantages of using the targeted delivery strategy for lymphatic uptake 
also apply to LN including dose sparing and minimizing the potential for undesirable off-
target effects and/or toxicities,[102] these data support the concept that despite 
nanoformulations of an intermediate nanoscale size being ideal for lymphatic partitioning 
after injection in the periphery, small molecules have increased potential to travel freely 
within the LN cortex and elicit T cell responses. This model might be utilized to 
optimally target LN-resident cells via controlled release strategies of co-formulated drug 
such as the multi-stage release strategies that have previously been used to improve 
intratumoral drug penetration,[103] but have never been applied to LN delivery. 
2.3.4 Drug delivery vehicles for LN targeting 
Several immunotherapeutic schemes targeting LN have been developed (Figure 
2.2), with most approaches tested to date exploiting the drainage function of lymphatics 
as a delivery mechanism after administration in peripheral tissues. This principle has 
been explored for LN targeting using both synthetic materials, including 
nanoformulations comprised of Pluronic-stablized poly(propylene sulfide),[67, 104] 
polymer dendrimers[66, 100] and poly(γ-glutamic acid)-L-phenylalanine ethylester,[99] 
as well as biologically derived biopolymers, such as hyaluronic acid[105] and 
albumin.[102] Such approaches have been used to improve LN delivery and bioactivity 
of co-formulated small molecules,[106] oligonucleotides,[10, 102, 107] as well as 
proteins and peptides.[80, 102, 108] 
Micelles are composed of block copolymers that self-assemble to sizes from 
several nm to several hundred nm. Micelles offer the notable advantage in drug delivery 
applications of the ability to encapsulate hydrophobic drugs within their core and deliver 
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this cargo to tissues and cells.[71] For example, Reddy et al. explored the effect of 
increasing micelle size range on LN accumulation and retention over time. Micelles were 
synthesized at sizes of 20, 45, and 100 nm using PEG-stabilized poly(propylene sulfide) 
NP. 20 nm NP were most efficiently transported through the lymphatics to the LN 
compared to the 45 and 100 nm NP, and were furthermore retained longer within the LN 
up to five days post-injection.[67] Additionally, the cellular fate of the LN-retained NP 
was assessed and found to be exclusively with APCs, with reports of upwards of 50% of 
APCs being positive for 20 nm NP. This data demonstrated the size-based principles 
behind lymphatic-targeting of LN, and also hints at the cellular access afforded by such 
particulate delivery vehicles.[67]  
While this drug delivery strategy for LN delivery utilizes a highly used design 
criteria to optimally target lymphatics and therefore achieve LN accumulation, strategies 
that seek to overcome the drawbacks of the large particulate delivery vehicle once inside 
the LN have yet to be explored. In cancer such multi-stage release strategies have 
previously been for similar purposes, such as to improve intratumoral drug penetration, 
but these have yet to be applied to LN delivery.[109] Within tumor therapy multi-stage 
strategies exploit tumor pathologies including using the upregulation of specific enzymes, 
such as matrix metalloproteinases, which are responsible for much of the tissue 
remodeling in cancer[110] to achieve target site-restricted degradation of a carrier and 
release of loaded drug. A particularly innovative approach designed to facilitate increased 
intratumoral drug penetration is the degradation of tumor-accumulating NP ~100 nm in 
diameter to a smaller, more diffusive size regime via the proteolytic activity of matrix 
metalloproteinase within the tumor microenvironment.[103] The advantage of such a 
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multistage system is the ability to overcome perivascular entrapment by the dense 
collagenous extracellular matrix within solid tumors that stymies drug bioactivity.[68] 
Given the transport barrier similarities between the tumor perivasculature and the LN 
subcapsular sinus and reticular conduits, such a scheme has the significant potential to 
improve the LN penetration of immunotherapeutic drugs to deep immune cells including 
T cells. 
2.3.5 LN-targeted immunotherapies 
Immunotherapy encompasses the use of checkpoint inhibitors, cancer vaccines, 
and non-specific cancer immunotherapies and adjuvants,[97] alone or in combination 
therapy. Using multiple agents with synergistic activity has been proposed for a variety of 
indications. The rationale is that co-treatment with drugs that exert complementary or 
orthogonal signaling function may amplify the desired response. In other scenarios, 
multiple agents are required for functionality and necessitate co-delivery to the same cell 
population(s).[1, 97] 
Among the promising cancer immunotherapy solutions, vaccines are promising as 
they are the most effective form of immune modulation developed to date, and involve 
the conditioning of adaptive immune response via multiple immunological signals. In its 
most basic form, vaccination entails exposure of the immune system to attenuated or 
inactivated pathogen. Antigen, the substance or part of the pathogen to which the immune 
response is generated against, is taken up, processed, and presented by APCs to antigen-
specific lymphocytes that recognize the specific antigen.[111] The local immune 
microenvironment at the time of antigen presentation dictates the differentiation 
programs followed by proliferating lymphocytes. Nature has thus evolved APCs to 
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recognize numerous pathogen-associated molecular patterns such that upon exposure to 
pathogen these cells become activated, produce stimulatory cytokines, and surface 
express maturation co-stimulatory molecules.[112] Hence, antigen-specific lymphocytes 
proliferate as the result of antigen recognition in an immune stimulatory 
microenvironment, driving the induction of robust adaptive immunity.[111]  
In order to mimic the effects of such vaccination strategies using a technology 
with finer-tuned control of dose for improved safety, engineered material systems have 
been developed. Formulations that enhance the delivery of both antigen and the immune 
stimulatory signal, termed an adjuvant, to their same target cells, and to ensure their 
efficient synergistic interactions, have been explored in an approach called “co-delivery” 
(Figure 2.2).[113] Anionic polymerization of propylene sulfide can be carried out within 
micelles composed of Pluronic F127, an amphiliphic block copolymer made from PEG-
poly(propylene glycol)-PEG.[114] The resulting 30 nm diameter poly(propylene sulfide) 
NP have been explored in several applications for their capacity of deliver 
immunotherapeutic drugs to LN for immunomodulation. In de Titta et al.[107] toll-like 
receptor (TLR) 9 ligand CpG oligonucleotides were conjugated to these polymer NP. 
Upon footpad injection, NP-conjugated CpG elicited a more potent maturation response 
of draining LN-resident dendritic cells relative to free CpG. Furthermore, when co-
injected with NP conjugated to the chicken ovalbumin protein (OVA), treatment with 
CpG-conjugated NP more potently induced antigen-specific effector and memory T cell 
responses relative to treatment with free CpG. Capitalizing on this T cell activation, 
vaccinated mice were challenged with OVA expressing murine lymphomas and 
melanomas and a significant retardation in tumor formation was found in mice vaccinated 
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with OVA-conjugated NP co-infused with CpG-conjugated NP rather than free CpG. 
These results emphasize the potential for LN delivery to improve the potency of cancer 
vaccines.[107] 
Taking this concept a step further, in Thomas et al. the use of endogenous tumor 
antigen was exploited for therapeutic vaccination against cancer. In the previous work 
tumor antigen was co-delivered with adjutant to induce a potent anti-tumor immune 
response. However, the tumor-draining LN (TDLN) is known to be bathed in tumor-
derived antigen,[115] and therefore the LN-resident cells may already be in a state of 
activation against endogenous tumor antigen, requiring only then the delivery of adjuvant 
to elicit a robot anti-tumor immune response. Elaborating upon this integral role of the 
TDLN in tumor immunity,[116] Thomas et al. explored how the sole delivery of 
immunotherapeutic adjuvant drugs to the TDLN vs. non-TDLN influenced tumor 
progression and development of anti-tumor immunity without delivery of exogenous 
antigen.[10] In this work, tumor lymphatic drainage was biased by implanting murine 
B16F10 melanomas in the left dorsal skin of mice, thereby focusing lymphatic drainage 
to the tumor-draining ipsilateral LN and creating non-TDLN on the contralateral side. 
When fluorescently-labeled, the aforementioned poly(propylene sulfide) NP were found 
to accumulate appreciably only in LN ipsilateral to the site of intradermal injection. With 
daily administration in the dermis ipsilateral to the tumor, adjuvant drug-loaded NP 
resulted in a slowing of tumor growth not observed when administered intravenously or 
in the skin contralateral to the tumor. The NP-mediated delivery to the LN was crucial to 
this effect since treatment with free drug with or without NP co-infusion had no influence 
on tumor growth. These differences in efficacy were attributed to the observed increases 
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in the maturation and activation status of dendritic and T cells resident within the TDLN. 
Correspondingly, drug loaded NP delivery to TDLN boosted the adaptive immune 
response to endogenously produced tumor antigen that also accumulated within TDLN, 
as indicated by an increased frequency of tumor infiltrating antigen-specific T CD8+ 
cells. These results illustrate the potential for TDLN-targeted drug delivery for tumor 
immunotherapy.[10] 
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CHAPTER 3. S-Nitrosated Polypropylene Sulfide Nanoparticles for 
Thiol-Dependent Transnitrosation and Toxicity Against Adult 
Female Filarial Worms[13] 
 
3.1 Introduction 
NO mediates its effects through its chemistry in a variety of physiological 
signaling processes including vasodilation,[117] inhibition of platelet aggregation,[118] 
and cytotoxicity[36] in a manner analogous to phosphorylation.[52] NO is highly 
diffusive, but due to its chemical reactivity is purported to have an extremely short half-
life on the order of 5–10 s.[63] Controlled delivery and release strategies for NO are thus 
highly attractive for a range of therapeutic applications,[119-121] but challenging to 
achieve within deep tissue targets.[29] 
To enable NO’s physiological effects to be exerted over much farther distances 
than its reactivity-limited diffusion distance would permit, NO in situ can form reversible 
adducts with endogenous nucleophiles[23] or convert to its more stable oxidized forms, 
nitrite (NO2
−
) and nitrate,[122] all of which can revert to NO under certain physiological 
conditions.[122, 123] Endogenous R-SNO, which include S-nitrosocysteine (SNO-CYS), 
S-nitroso-albumin, and S-nitrosoglutathione, represent a major class of NO adducts that 
facilitate NO’s transport in vivo.[51] R-SNO are formed on free thiols either through 
reactions with nitrosating agents[54, 124] or by transnitrosation (i.e., by transfer of NO 
from other nitrosothiols)[55, 56] giving R-SNO the ability to be formed under a wide 
range of (patho)physiological conditions.[57] Therefore, in addition to NO2
−
 and nitrate, 
which have previously been explored for therapeutic delivery as prodrugs,[125] R-SNO 
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represent an attractive and physiological NO chemistry that has been exploited to harness 
both native NO signaling and transport activity in biological systems.[50] 
Brugia malayi , one of three filarial worms responsible for lymphatic filariasis, 
are transmitted through a mosquito’s saliva, injected into a host’s dermis, where they 
make their way to the lymphatics, grow and multiply, and can eventually cause several 
chronic diseases including elephantiasis.[126] There are an estimated 120 million people, 
most of whom reside in the developing world, who harbor these parasites with another 1 
billion people identified as at risk for infection.[3] While there are several treatment 
options available to remove the microfilaria progeny that spread the disease, there are no 
lymphatic localized therapies that target the adult worms in the lymphatics where they 
reside. Hence, people currently infected face few treatment options.[3] 
NO has been implicated as an effector cytotoxic molecule in the immune response 
to a variety of pathogenic parasites.[126-128] Previous work has shown that B. malayi 
are susceptible to exogenously delivered NO[129] and demonstrated potential for 
physiological R-SNO, SNO-CYS,[130] and S-nitrosoglutathione,[131] to mediate 
damage to several types of parasites. Due to their small size, however, commercially 
available NO donors and physiological R-SNO have low potential after injection to 
accumulate within lymphatic vessels[11, 15, 132, 133] where these parasites reside, 
curbing their utility as antifilarial therapeutic agents. Whereas small molecules < 5 nm in 
hydrodynamic size are freely blood permeable and are thus rapidly cleared into the 
systemic circulation,[11] drug targeting to lymphatics is significantly enhanced for 
nanoscale drug delivery systems ≈30 nm in hydrodynamic size[11] and NO formulation 
approaches improve both donor circulation times[6] and NO bioactivity.[72] A NO-
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encapsulating nanoformulation could therefore facilitate the targeted, controlled, and 
efficient delivery of NO to eradicate filarial parasites resident within lymphatic tissues. 
Herein, we report the synthesis and modification of thiolated NP with NO in order 
to harness the physiological nitrosothiol chemistry for NO delivery and bioactivity using 
a synthetic polymer system. These NO-containing NP, SNO-NP, stably encapsulate high 
levels of NO and facilitate its controlled release. In particular, we demonstrate that the 
bioactive form of released NO from SNO-NP, either NO2
− 
or SNO-CYS, depends on the 
ratio of free CYS, a common endogenous low molecular weight thiol important in 
transnitrosation reactions,[57] to SNO-NP. Furthermore, the cytotoxic activity of 
SNO-NP against B. malayi adult female filarial worms, for which there is no existing 
treatment, is accelerated in the presence of CYS due to the formation of SNO-CYS. Since 
these synthetic NP have well-documented lymphatic targeting activity after intradermal 
injection,[10] these results provide a strong rationale for therapeutic use of SNO-NP in 
eradication of B. malayi that reside intralymphatically in vivo and for other deep tissue 
NO delivery applications. 
3.2 Materials and Methods 
3.2.1 Synthesis and characterization of SNO-NP 
NP were synthesized as previously described.[10, 114, 134] Briefly, 500 mg of 
Pluronic F127 (Sigma-Aldrich, St. Louis, MO, USA, P2443) was added to 10 mL of 
degassed Milli-Q water, allowed to dissolve for 30 min with stirring, and was again 
degassed. To this solution, 400 μL of propylene sulfide (Sigma-Aldrich, P53209) was 
added under argon and stirred for 30 min. Initiator weighing 7.8, 14.4, 28.8, or 43.4 mg 
(1.9, 3.7, 7.4, and 11 × 10
-3
 M , respectively) was reacted with 322 μL of sodium 
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methoxide (Sigma-Aldrich, 156256) and then added under argon. 1,8-Diazabicyclo[5.4.0] 
undec-7-ene (DBU) (Sigma-Aldrich, 139009) was added under argon to the solution 15 
min later and the entire reaction stirred for 24 h. The solution was subsequently exposed 
to air for 2 h and dialyzed for 3 d against 4 × 5 L of Milli-Q water using 100,000 Da 
molecular weight cut off cellulose membrane dialysis tubing (Spectrum Lab., Rancho 
Dominguez, CA, USA, 131414). NP size was measured by dynamic light scattering and a 
small volume was lyophilized to obtain the total NP weight concentration. 1 H NMR 
(400 MHz, CDCl3) was used to calculate the weight percent of Pluronic F127, 
poly(propylene sulfide), and initiator in the NP.[134] Ellman’s assay (Thermo Scientific, 
Rockford, IL, USA, 22582) was used to determine the concentration of NP free thiols. 
Thiolated NP were S-nitrosated by reacting equal volumes of NP with sodium nitrite 
(Sigma Aldrich, 237213) solution in strong acid. Unreacted free acidified nitrite was 
capped with addition of ammonium sulfamate (Sigma Aldrich, 228745). SNO-NP were 
further dialyzed before use in transnitrosation and B. malayi experiments.  
3.2.2 Determination of SNO and NO2
−
 concentration using modified Saville and Griess 
assays 
Acidified nitrite solution was prepared by mixing equal volumes of 2 N HCL with 
sodium nitrite solution (aqueous). Sulfanilamide (Sigma-Aldrich, S9251) solution was 
prepared by dissolving 34 mg sulfanilamide in 1 mL of 0.4 N HCL. Mercuric chloride 
(Sigma-Aldrich, 215465) solution was prepared by dissolving 10 mg of mercuric chloride 
in 1 mL of water. N-(1-naphthyl)ethylenediamine dihydrochloride (Sigma-Aldrich, 
222488) solution (5.4 × 10
-3
 M ) was prepared in 0.4 N HCL. In reactions where excess 
acidified nitrite was removed, an eightfold molar excess of ammonium sulfamate was 
added to the solution. The Saville assay,[135] which measures S-nitrosothiol 
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concentration, was performed by mixing 70 μL of the S-nitrosated thiol solution with 
100 μL of Solution A (one part mercuric chloride solution and four parts sulfanilamide 
solution) or 100 μL of Solution B (one part water and four parts sulfanilamide solution) 
and then mixing these solutions with 80 μL of 5.4 × 10
−3
 M N-(1-
naphthyl)ethylenediamine dihydrochloride solution. The Griess assay, which measures 
free NO2
−
, is the same as the Saville, except without the addition of Solution A. For both 
assays, after a 10-min incubation at room temperature, the absorbance was read at 540 
nm and the difference between Solution A and Solution B represents the S-nitrosothiol 
signal. S-nitrosothiol and free NO2
− 
concentrations were calculated from a standard curve 
of S -nitrosoglutathione.[136] 
3.2.3 Degradation and transnitrosation studies 
SNO-NP were prepared by the standard S-nitrosation procedure described above. 
SNO-NP were then dialyzed with 100,000 Da molecular weight cut off cellulose 
membrane dialysis tubing against 5 L of Milli-Q water overnight. Following dialysis, 
SNO-NP were brought to pH 7.4 using 10× phosphate buffer saline (PBS) without 
calcium and magnesium and diluted to 1–2 × 10
−3
 M NO concentration in complete 
medium. S-nitroso-N-acetyl penicillamine (SNAP) solutions were made in PBS, pH to 
7.4, and diluted to 1–2 × 10
−3
 M NO concentration in complete medium. SNO-NP in 
complete medium were mixed with CYS to 0.1, 1, and 10× the SNO-NP concentration. 
Solutions were incubated in closed vessels at 37°C and nitrite and SNO concentrations 
monitored over 100 h. Transnitrosation studies were conducted as described above except 
SNO-NP were incubated in the presence of varying amounts of CYS for 45, 365, and 
1460 min at 37°C, after which 250 μL of the solution was fractionated on a 1 cm × 30 cm 
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Sepharose CL-6B (GE Healthcare, Pittsburg, PA, USA, 17-0160-01) column. Eluted 
fractions were analyzed for NO2
− 
and SNO using the Griess assay and Saville assay, 
respectively. 
3.2.4 Brugia malayi motility and death studies 
Freshly isolated adult female B. malayi parasites were obtained from the National 
Institutes of Health Filarial Research Resource (FR3)[137] at the University of Georgia 
(Athens, GA, USA). Upon receipt, worms were washed and resuspended in 50 mL of 
complete medium (endothelial basal medium (Lonza, New York, USA) supplemented 
with 20% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA), 1% 
glutamax, 1% penicillin-streptomycin-amphotericin (Gibco, New York, NY, USA), 25 
mg/mL cyclic-AMP and 1 mg/mL hydrocortisone acetate (both from Sigma-Aldrich)). 
The worms were then maintained at 37°C in a 5% CO 2 incubator for at least 18 h prior 
to experimentation. Individual worms were subsequently plated in 2.5 mL of complete 
medium in a 24-well culture plate preincubated at 37°C in a 5% CO 2 for 1 h prior to the 
addition of worms. All treatment solutions were prepared the day of the experiment, 
except SNO-NP, which were S-nitrosated and dialyzed the prior evening. All treatment 
solutions were prepared in 1 × PBS without calcium and magnesium at a pH of 7.4. 
500 μL of each treatment was added to the worms in replicates of four. Following the 
addition of treatments, the worms were incubated and 5 s video segments at 10 min 
intervals were recorded using a custom imaging hardware assembled and maintained 
within the incubator. Worm motility was quantified using a Lucas-Kanade optical flow 
algorithm implemented in LabVIEW (National Instruments, Austin, TX). The velocity 
vectors obtained between two subsequent frames were summed for an entire worm-
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containing well and then averaged over the length of the video segment giving us the 
motility metric. Worm death was defined when the motility metric (normalized to 
pretreatment baseline) fell and remained below 10% of its normalized value. The 10% 
threshold was used after it was determined that below that the algorithm was quantifying 
noisy pixels due to vibrations in the incubator. Data representative of individual treatment 
groups run in quadruplets in two to five independently run experiments. 
3.2.5 Statistical analysis 
Data are expressed as mean ± standard deviation. Statistical analysis was carried 
out using Prism 6 (GraphPad Software Inc. La Jolla, CA, USA). Death curves were 
analyzed using a Log-rank (Mantel-Cox) test for significance. Time until death was 
analyzed using an ordinary unpaired one-way analysis of variance (ANOVA) with Tukey 
multiple comparison correction. Statistical significance was defined as and represented 
by p ≤ 0.05 (*), p ≤ 0.01 (**), and p ≤ 0.001 (*** and §§§). 
3.3 Results and Discussion 
3.3.1 SNO-NP synthesis and characterization 
SNO-NP were formed by S-nitrosation of synthetic thiolated NP synthesized by 
emulsion polymerization[134] (Figure 3.1a). Amphiphilic block copolymer Pluronics, 
including F127 (PF127) explored here as well as F68,[138] self-assemble in water to 
form micelles, which are able to make an emulsion with propylene sulfide and, in the 
presence of a deprotected thiolated initiator, activate living anionic polymerization within 
the micelle core.  
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Figure 3.1: Synthetic polymer NP are loaded with NO through the formation of 
physiological NO adducts, S -nitrosothiols (SNO), with NP SH. a) NP synthesis and 
S-nitrosation scheme to create S-nitrosothiol (SNO) NP (SNO-NP). b) Particle SH 
concentration is controlled by initiator concentration during emulsion 
polymerization synthesis. c) NP diameter remains unchanged by SH concentration 
and NO loading. d) SNO concentration and number per NP is proportional to NP 
SH concentration. NP-encapsulated NO is e) in the form of SNO as demonstrated by 
UV absorbance peaks at 340 and is f) NP bound. e) Arrow indicates increasing 
SNO-NP concentration. Data shown for a highest SNO-NP concentration of 5.6 × 
10
−3
 M with approximate twofold dilutions. Inset demonstrates calculation of molar 




. g) Whereas nitrite (NO2
−
) 
remaining after S-nitrosation of SH-NP is rapidly dialyzed away, SNO signal by the 
Saville assay is retained.[13] 
As the concentration of initiator was varied, different degrees of polymerization 
of poly(propylene sulfide) (PS) were achieved (Figures 3.2 and 3.3a-c). This resulted in 
an increasing concentration of free thiols (SH) (Figure 3.1b) as well as ratio of SH to 
disulfide (Figure 3.3d) at the completion of polymerization after solution oxidation with 





H NMR data of lyophilized NP solution. The following have been 
assigned according to van der Vlies et al.[134] as the functional group peaks: 1.1 
ppm – CH3 Pluronic (-CH2-CH(CH3)-O-), 1.4 ppm – CH3 poly(propylene sulfide) (-
CH2-CH(CH3)-S-), 2.7 ppm – CH2 initiator (-C-CH2-S-), and 3.7 ppm – CH2 PEG (-
CH2-CH2-O-). The integral of each peak is displayed under the axis. Normalizing 
each integral to the number of H atoms (3, 3, 2, and 4 respectively) and multiplying 
by the weight of the functional group allows for the mass percentage of NP solution 
and degree of polymerization to be determined. Pluronic is taken as the combination 
of the -CH2-CH(CH3)-O- and -CH2-CH2-O- fragments.[13] 
Dialyzed NP were subsequently S-nitrosated by introduction of acidified nitrite, 
enabling formation of NO S-nitroso adducts (SNO) with the NP core free thiols. With 
increasing concentration of NP SH there was a proportional increase in SNO 
concentration created as measured by a modified Saville assay,[56] indicating efficient 
S-nitroso adduct formation (Figure 3.1d) that was determined to be >90% for all starting 
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NP free thiol concentrations. This occurred with no change in NP size (Figure 3.1c) and 
resulted in up to an estimated 2000 SNO per NP (Figure 3.1d). To confirm SNO adduct 
formation within NP, SNO-NP were analyzed via UV-vis absorbance. SNO-NP exhibited 
the characteristic absorbance wavelength of primary thiol S-nitroso adducts at ≈340 
nm,[73] that increased with concentration (Figure 3.1e) giving a molar extinction 




 (Figure 3.1e, inset) consistent with previously reported 
R-SNO.[55] Furthermore, the SNO signal coeluted with that of the thiolated NP during 
column chromatography (Figure 3.1f), demonstrating the stability of the SNO adduct. 
Additionally, over the course of dialysis at room temperature against water in a 
membrane with a 100,000 molecular weight cut-off (MWCO), SNO signal did not 
decline appreciably while free NO2
−
 from the S-nitrosation process was effectively 
removed as the pH of SNO-NP was brought to physiological levels (Figure 3.1g). 
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Figure 3.3: Characterization of NP polymerization reaction, S-nitrosothiol decay, 
and transnitrosation. a) Lyophilization data showing that the total NP polymer 
weight/mL is unaffected by initiator concentration. 100 µL samples of NP solution 
synthesized under different initiator concentrations were lyophilized and the weight 
percent of polymer was determined. b) Increasing initiator concentration during 
polymerization results in increasing the weight percent of initiator incorporated into 
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the NP solution. NP were synthesized under different initiator concentrations and 
lyophilized. The weight percent of each constituent component, Pluronic F127, 
poly(propylene sulfide), and initiator were determined using 
1
H NMR (Figure 3.2). 
c) Degree of polymerization of propylene sulfide increases as molar ratio of 
propylene sulfide to initiator is increased. NP were synthesized with different 
initiator concentrations, lyophilized, and analyzed via 
1
H NMR (Figure 3.2). Using 
specific peak assignments and normalizing each peak to the number of hydrogen 
atoms per repeat group, the total number of poly(propylene sulfide) groups and 
initiator groups were determined. Taking the ratio of poly(propylene sulfide) groups 
to initiator groups and dividing by the number of arms per initiators (four), the 
number of poly(propylene sulfide) repeats per initiator and the degree of 
polymerization were determined. d) The ratio of thiol to calculated disulfide bond 
concentration increases with increasing initiator thiol concentration. NP were 
synthesized with different initiator concentrations. Assuming no initiator loss, the 
ratio between the measured final free thiol concentration and remaining disulfides 
as determined by the added amount of initiator thiols was determined. e) 
Degradation of SNO-NP at 37°C is unaffected by degree of polymerization. SNO-NP 
synthesized with 7.4 and 11 mM initiator, corresponding to degrees of 
polymerization (DP) of 65.7 and 44.2, respectively, showed similar rates of NO 
release at 37°C. f) The extent of transnitrosation of SNO-NP to CYS at 37°C is 
unaffected by degree of polymerization. SNO-NP synthesized with 7.4 and 11 mM 
initiator, corresponding to degrees of polymerization (DP) of 65.7 and 44.2, 
respectively, showed similar extents of transnitrosation to CYS over time at 
37°C.[13] 
3.3.2 SNO-NP S-nitrosothiol decomposition and transnitrosation 
We next explored the release of NO from SNO-NP under physiological 
conditions. In complete serum-containing media at 37°C, decay of SNO signal from 1 × 
10
−3
 M of SNO-NP over 100 h was comparable to that of 1 × 10
−3
 M of SNAP, a 
commercially available synthetic small molecule NO donor[123] that is similar in size 
and structure to some endogenous R-SNO, which has been extensively used to study a 
wide variety of NO-regulated processes including inflammation,[138] vasodilation,[139] 
and inhibition of platelet aggregation.[123] The rate of NO release from SNO-NP was not 
influenced by the degree of PS polymerization (Figure 3.3e). However, at 6 and 24 h post 
incubation, SNO-NP exhibited faster release (32% and 70%, respectively) of SNO 
relative to SNAP (7% and 50%) (Figure 3.4a). In distinct contrast to SNAP, SNO-NP 
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also resulted in the significant accumulation over time of NO2
−
 (Figure 3.4a), likely 
resulting from preferential reaction with oxygen due to its increased concentration within 
the hydrophobic NP core, in which oxygen is more soluble than aqueous media.[140] 
SNAP, on the other hand, being a small molecule NO donor that releases NO directly 
into a less oxygen dense environment[23] that may have potential for interactions with 




Figure 3.4: SNO-NP mediate transnitrosation under high but not low concentrations 
of physiological SH CYS in complete medium at 37°C. a) Under conditions of no 
exogenously added CYS, decay of SNO from SNO-NP is comparable to that of low 
molecular weight NO donor, S-N-acetyl penicillamine (SNAP) but results in 
formation of nitrite (NO2
−
). b,c) High (10:1) but not low (0:1, 0.1:1, and 1:10) ratios 
of CYS to SNO-NP result in long-lived SNO species (b) and minimal SNO-NP 
release of NO2
−
 (c). d) Scheme of free thiol (CYS)-dependent NO release from 
SNO-NP to form NO2
− 
or SNO-CYS via transnitrosation. e) Column 
chromatography fractionation of NP and CYS at various CYS:SNO-NP ratios 
reveals increased formation of SNO-CYS with increasing coincubation time and 
increasing CYS:SNO-NP ratio f,g). a-c) * p < 0.05 and ** p < 0.01 by two-way 
ANOVA with matching and post hoc Bonferroni tests. f,g) *, §, † p < 0.05 by two-
way ANOVA with matching and post hoc Bonferroni tests relative to 0.1:1 at 1460 
min, 0.1:1 at 375 min, and 1:1 at 375 min, respectively. In all experiments, a 
SNO-NP concentration of 1 × 10
−3
 M SNO was used.[13] 
We next evaluated whether SNO-NP could donate NO to physiological thiols 
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through transnitrosation.[55] In complete medium, the free thiol concentration was found 
to be <0.025 × 10
−3
 M as measured by Ellman’s assay. To probe how the presence of free 
thiols may drive transnitrosation, we added CYS and monitored SNO decay from 
SNO-NP and the formation of NO2
−
 over time (Figure 3.4b,c). CYS was mixed with 1 × 
10
−3
 M of SNO-NP at the following ratios of CYS:SNO-NP (i.e., SH from CYS to SNO 
from SNO-NP): 0:1, 0.1:1, 1:1, and 10:1. CYS to SNO-NP ratios of 1:1 and 10:1 
accelerated the decay of SNO signal from SNO-NP relative to low and zero CYS ratios 
(Figure 3.4b). However, an increase in SNO signal that was not statistically significant 
was observed at long times after coincubation for the highest ratio tested (10:1, Figure 
3.4b), suggesting long lived SNO species under conditions of excess CYS. Furthermore, 
whereas low CYS to SNO-NP ratios (0.1:1, 1:1) resulted in the appreciable accumulation 
of NO2
−
 in a manner analogous to NO release by SNO-NP with no added CYS, a 10:1 
ratio of CYS to SNO-NP did not (Figure 3.4c). These data suggest that under conditions 
of low vs. high CYS, NO is released from SNO-NP by either of two distinct pathways: to 
NO2
–
 in the case of low or no free thiols or to R-SNO via transnitrosation in the case of 
high thiol concentration (Figure 3.4d). 
To test this hypothesis, the extent of transnitrosation as determined by the 
formation of SNO-CYS after coincubation of 1 × 10
−3
 M of SNO-NP with varying ratios 
of CYS was determined. Since the Saville assay could not discriminate between SNO 
retained by SNO-NP vs. that from newly created SNO-CYS via transnitrosation, the two 
SNO species were separated using size exclusion column chromatography after 
prescribed times of coincubation. This technique was able to detect the ratio of remaining 
SNO amongst the two species, SNO-NP and SNO-CYS, by comparing the collected 
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fractions to those previously obtained for the individual species (Figure 3.4e). By virtue 
of their larger size, NP eluted in early fractions, whereas small CYS eluted in later 
fractions as verified by Ellman’s assay and iodine staining.[10] We found that SNO-CYS 
constituted a larger percent of remaining SNO at late times for all CYS to SNO-NP ratios 
tested but only represented a significant portion of the remaining SNO for 10:1 
CYS:SNO-NP (Figure 3.4f). In terms of absolute amount, this corresponded with an 
appreciable increase in SNO-CYS concentration for only the 10:1 CYS to SNO-NP 
(Figure 3.4g). The extent of transnitrosation by SNO-NP was not appreciably affected by 
degree of PS polymerization (Figure 3.3f). 
3.3.3 SNO-NP biological activity in filarial worm model 
To demonstrate SNO-NP function as an antiparasitic agent, we devised a setup in 
which adult female worms were individually incubated in wells containing complete 
medium and quantified motility over 96 h. We have previously used a similar 
experimental configuration to monitor worm motility and health over time as well as 
evaluate worm responses to antiparasitic agents.[142] Worm motility in response to 
treatment normalized to pretreatment was then plotted over time. Concentrations of NO 
treatment groups ranged from 1× 10
−3





Figure 3.5: SNO-NP-mediated killing of adult female B. malayi filarial worms is 
accelerated with increasing ratios of low molecular weight thiol CYS to SNO-NP. a) 
Worm motility is reduced by NO donors SNO-NP and b) S-N-acetyl penicillamine 
(SNAP) and results in worm death at similar times. c) Increasing ratio of CYS to 
SNO-NP accelerates SNO-NP-mediated reductions in worm motility. d,e) Worm 
death induced by SNO-NP occurs more quickly at the highest ratios of CYS to 
SNO-NP relative to SNAP. Data in all panels from at least two independently run 
experiments. a,c) Data represent the average motility of n ≥ 8 worms. b,d) *** and 
§§§ p < 0.001 by Log-rank test. e) * p < 0.5 by one-way ANOVA with 
multiparameter comparison correction (Tukey’s test). f) Shortest time until worm 
death induced by SNO-NP corresponds to the ratio of CYS to SNO-NP that results 
in the highest observed levels of formed SNO-CYS concentrations. In all 
experiments, SNONP and SNAP concentrations of 1–2 × 10
−3
 M SNO were used.[13] 
We found that the motility of SNAP-treated worms decreased quickly upon 
coincubation with SNAP, while control N-acetyl penicilamine (NAP)-treated worms 
showed no reduction (Figure 3.5a). Treatment with SNO-NP but not NP alone also 
resulted in a reduction of worm motility though the response was much delayed relative 
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to SNAP (Figure 3.5a). However, the death curve (Figure 3.5b) and the time until death 
(Figure 3.5e) defined as when motility dropped below 10% of baseline, were similar for 
both SNAP and SNO-NP-treated worms. We hypothesized that this discrepancy in effect 
on motility but not time until death may result from SNAP but not SNO-NP penetration 
into the worms in order to mediate its effects. This idea is supported by findings that the 
worm’s cuticle, the highly cross-linked collagenous structure lining the worm’s limiting 
membrane,[143] is impermeable to large antibody and complement complexes,[144] but 
not to small molecules such as glucose or amino acids, thus making it impermeable to the 
SNO-NP.[145] Furthermore, it has been previously hypothesized that endogenous 
R-SNO, which are similar in molecular weight and hydrodynamic size to SNAP, mediate 
antiparasitic effects through their uptake by worms as the result of their similarity to 
natural analogues[130] and by S-nitrosating key proteins[146] such as cysteine 
proteases.[128, 147] To test this hypothesis, worms were incubated with SNO-NP in the 
presence of 0:1, 0.1:1, 1:1, and 10:1 CYS:SNO-NP. Treatment with CYS alone did not 
have a negative effect on worm motility and did not result in any worm death. When 
worms were incubated with SNO-NP at a 0.1:1 ratio with CYS, a similar effect on worm 
motility as that of SNO-NP alone (Figure 3.5c) was found. However, when CYS was 
present at a 1:1 ratio, the reduction in motility closely matched that induced by SNAP 
(Figure 3.5c). Intriguingly, when CYS was present at the ratio 10:1 with SNO-NP, the 
reduction in motility induced by treatment was almost immediate (Figure 3.5c) and 
resulted in a dramatically faster time until death than that of SNAP (Figure 3.5e). Worm 
treatment with SNO-NP in combination with increasing amounts of CYS up to a ratio of 
1:1 resulted in the same death curve as SNAP relative to PBS (Figure 3.5d). However, 
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treatment with SNO-NP in combination with CYS at the highest ratio tested (10:1) 
resulted in death curves that were accelerated relative to those induced by treatment with 
other CYS:SNO-NP ratios and SNAP (Figure 3.5d). This significant difference, as 
exemplified by the rapid time until death of 10:1 CYS:SNO-NP (Figure 3.5e), may be a 
result of the higher amount of total SNO-CYS created when CYS is added at a high ratio 
relative to SNO-NP (Figure 3.5f). Although cysteine is present in the lymph at ≈100 × 
10
−6
 M,[148] SNO-NP undergo significant dilution following intradermal administration, 
accumulating within lymph in draining LN at a ≈30–100-fold lower concentration 
relative to that administered in the dermis.[10] Hence if the dose used in vitro here was 
administrated intradermally, SNO-NP would still result in CYS:SNO-NP ratios >3–10. 
Additionally, SNO-CYS (187 Da), which is approximately the same size as SNAP (220 
Da), may kill the worms faster either because it is absorbed more quickly than SNAP or 
because it is better at mediating the effects of the NO it carries. In addition to their higher 
potential for lymphatic targeting relative to SNAP, these results highlight the potential for 
SNO-NP to effectively treat parasites through its unique NO-releasing mechanisms. 
3.4 Conclusions 
In conclusion, we have demonstrated the synthesis and characterization of 
SNO-NP for the delivery of NO reservoirs NO2
−
 and R-SNO. We demonstrate that 
SNO-NP release SNO through either the formation of NO2
−
 or by transnitrosation. 
Furthermore, we establish antiparasitic activity of SNO-NP corresponding with the extent 
of R-SNO formation determined by the relative ratio of CYS to SNO-NP (Figure 3.5f). 
Implementing a synthetic polymer nanoformulation to deliver high levels of per NP NO 
via the physiological S-nitrosothiol chemistry represents an innovative approach to 
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achieve therapeutic delivery of NO. Given the unique and previously reported lymphatic 
targeting activity of these NP, this represents a novel formulation for the delivery of NO 




CHAPTER 4. S-nitrosated poly(propylene sulfide) Nanoparticles for 
Enhanced Nitric Oxide Delivery to Lymphatic Tissues[149] 
 
4.1 Introduction 
The lymphatics are involved in a wide variety of diseases either as the primary 
tissue of interest, such as with lymphedema[2] or lymphatic filariasis,[3] or as an 
accessory to the pathologies of other diseases, such as with myocardial infarction[4, 5, 
150] and cancer.[10] Due to the integral role lymphatics play in tissue fluid regulation,[6] 
lipid transport,[7] and immune cell functions,[8, 9, 151] an estimated forty million 
patients worldwide[20, 21] endure the combined effect of all diseases in which the 
lymphatics are affected. Despite the high prevalence of lymphatic-associated diseases, 
treatment methods, especially for diseases where the lymphatics are the primary tissue of 
interest, remain stagnated or in some cases nonexistent. As one example, the current 
standard for the treatment of lymphatic filariasis, an infection of lymphatic tissues by 
parasitic worms, is the use of antibiotic cocktails that distribute systemically to eliminate 
the microfilaria offspring that spread disease but do not result in appreciable drug 
accumulation within the lymphatics where the adult worms reside.[3] Moreover, standard 
therapy for lymphedema, one of the morbidities associated with both lymphatic filariasis 
infections and sentinel LN removal following breast tumor resection, employs only a 
combination of compression and physical therapy.[22] For diseases where the lymphatics 
are not the primary target but are critically involved in the disease pathology or may be 
useful therapeutically, such as immunotherapy[10, 152-154] or LN-directed 
chemotherapy (e.g., for the treatment of sentinel LN metastases),[155] there exist few 
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approved treatments that are specifically formulated to enhance delivery to lymphatics, 
leaving open the possibility of a range of undesired consequences including reduced 
treatment efficacy and toxicities related to accumulation in off target tissues.[156] 
A therapeutic of particular interest for the treatment of lymphatic-related diseases 
is NO, an extremely promiscuous signaling molecule that takes part in a variety of 
physiological processes ranging from vasodilation,[58, 117, 118, 157, 158] to neural 
signaling,[29] to immune cell cytotoxic defenses.[31, 35, 46, 159] Because of the 
important role that NO plays in multiple physiological processes, there have been many 
attempts at modulating NO for therapeutic purposes. For example, NO delivered in the 
form of nitrate is used to control pain from angina, a disease affecting nine million people 
in the US with 500,000 new cases every year, and has been found to annually cost the 
healthcare system around $1.9 billion.[37] NO has also been investigated in several 
clinical trials for use with other cardiovascular treatments to control blood pressure in 
adults with prehypertension,[39] which affects 25–50% of adults worldwide,[40] and to 
improve the function of the right of the heart following heart transplant or left ventricular 
assist device placement.[41] For pulmonary diseases NO is inhaled in its gaseous form, 
and is the current standard of care for persistent pulmonary hypertension in newborns, 
which affects 1.9 per 1000 live births.[42] NO has also been explored for the treatment of 
various cancers, including lymphoma where a variety of NO donors have been shown to 
be chemosensitizers[43-45] as well as exhibit direct cytotoxicity.[45-49] 
Despite the versatility of NO as a potential therapeutic in a broad array of 
pathologies, several challenges exist with utilizing NO for lymphatic-related therapy. 
First, NO participates in many interrelated physiological processes that each have 
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different requirements for NO signaling.[29, 58, 59] In some cases depletion or 
attenuation of NO signaling may produce negative effects such as in vascular 
regulation,[60] whereas in the case of inflammatory responses overproduction of NO can 
lead to loss of lymphatic function.[31] Consequently, a lymphatic-targeted NO-based 
therapy would need to be tightly controllable, since NO levels vary significantly across 
physiological processes and pathologies.[24, 29, 61] Combined with the extremely short 
half-life[62, 63] of NO requiring it to mediate its action near its synthesis source,[62] 
targeted NO donation remains highly difficult. The second challenge to delivering NO, 
especially in the context of lymphatic-related therapies, is the result of the structure and 
location of the lymphatics.[9, 11] To focus delivery to within the locoregional lymphatic 
drainage basin, direct injection in the upstream peripheral tissue interstitium is most 
commonly utilized,[160-162] with uptake being most favorable for macromolecular 
species in the range of approximately 10–100 nm in hydrodynamic diameter.[163, 164] 
Since the significant majority of existing NO donors are small molecules and would thus 
exhibit poor selectivity for lymphatic uptake after administration in peripheral tissues,[9, 
11, 133, 163, 164] a critical technology gap exists in facilitating NO delivery to 
lymphatic tissues (Figure 4.1a). 
We previously developed[13] a NO encapsulation strategy that utilizes NP 
comprised of synthetic polymers that have well described profiles of lymphatic 
uptake[67] and biodistribution into lymphatic tissues.[104] We demonstrated that these 
S-nitrosated NP, that we refer to as SNO-NP, facilitate the controlled and sustained 
release of NO, enabling its cytotoxic activity against adult female Brugia malayi filarial 
worms, which are responsible for the lymphatic disease known as lymphedema.[3] 
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Herein, we report on the preclinical testing of the NO donating activity of these SNO-NP 
in an in vivo lymphatic delivery model. We measured over the course of 72 h the levels of 
various reactive nitrogen species (RNS) accumulating within systemic tissues, plasma, 
and LN draining the site of intradermal injection of SNO-NP and benchmarked against a 
commonly used, commercially available small molecule NO donor used for 
chemosensitization[Sullivan 2008] and radiosensitization of cancer,[43] S-nitroso D,L-
penicillamine (SNAP). We further assessed the impact of NO donation on lymphatic 
tissues by looking at lymphatic transport of NP and remodeling of the draining LN, 
including effects on LN-resident cells, as well as resulting inflammation at the site of 
injection and systemic toxicity. Our results show that donation of NO to LN when 
mediated by lymphatic-draining SNO-NP is dramatically improved relative to a small 
molecule NO donor and does not result in a measurable decrease in LN-resident cell 
viability or extent of NP uptake or increases in local or systemic levels of inflammation. 
4.2 Materials and Methods 
4.2.1 Materials 
All materials were purchased from Sigma-Aldrich unless otherwise noted. 
4.2.2 Synthesis and characterization of SNO-NP and SNAP 
Thiolated NP were synthesized as previously described.[13] Briefly, a 0.5% 
solution of pluronic F127 was made in degassed Milli-Q water. To this solution, 400 mL 
of propylene sulfide was added under argon and stirred for 30 min, after which, initiator 
weighing 14.4, 28.8, or 43.4 mg (3.7, 7.4, and 11 mM, respectively) and reacted with 
322 mL of sodium methoxide added under argon. 1,8-diazabicyclo[5.4.0] undec-7-ene 
was added under argon to the solution 15 min later and the entire reaction stirred for 24 h. 
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The NP solution was exposed to air for 2 h following the reaction and dialyzed for 3 days 
against 4 x 5 L of Milli Q water using a 100,000 Da molecular weight cut off cellulose 
membrane dialysis tubing (Spectrum Lab., Rancho Dominguez, CA, USA, 131414). The 
NP were S-nitrosated before each experiment by reacting equal volumes of NP with 
sodium nitrite solution in strong acid. Unreacted free acidified nitrite was capped with 
addition of ammonium sulfamate and purified from the SNO-NP solution using 7 kDa 
Zeba columns (Thermo Fisher). SNAP solution was prepared by dissolving SNAP in 1x 
PBS solution. S-nitrosothiol (SNO) concentrations in solutions were measured using the 
method of Saville (described below). For experiments that required fluorescent labeling 
of NP, NP were reacted with Alexa Fluor 647 C2 Maleimide (Thermo Fisher) followed 
by excess of N-ethylmaleimide (NEM) until free thiols were no longer detectable by 
Ellman’s assay. The solution was purified of free Alexa Fluor 647 and NEM using a 
PD-10 column (GE Healthcare, Pittsburg, PA, USA, 17-0851-01). NP size was 
determined by dynamic light scattering (Malvern Instruments). 
4.2.3 IVIS imaging 
Fluorescent imaging was performed with an IVIS® Spectrum instrument (Perkin 
Elmer). Animals were injected intradermally in the forearm with a solution of 
Alexa Fluor 647-NP or of SNO treatment group either with or without Alexa Fluor 647 
labeling. Twenty-four hours later the animals were sacrificed. To assess 
Alexa Fluor 647-NP drainage to LN, animals were imaged using Ex: 640, Em: 680 and 
an exposure of 0.1 s. For the SNO-NP colocalization experiment with NO, immediately 
after the animals were sacrificed, the skin was removed and 5 µL of a 1:1 solution of 
4-Amino-5-methylamino-2’,7’-fluorofluorescein diacetate (DAF-FM DA) (Cayman 
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Chemical), which works to identify NO through fluorescence due to the nitrosation of the 
diamino group resulting in a fluorescent triazole that has a 160-fold increase in 
fluorescent quantum yield and a fluorescence profile similar to fluorescein (FITC),[165] 
and 1% mercuric chloride was injected into the brachial LN on the right side. The 
animals were then immediately imaged for both the Alexa Fluor 647-NP using 647 
channel and DAF using the FITC channel (Ex: 500, Em: 540) at an exposure of 0.1 s. 
Total fluorescent counts and radiant efficiency (p/s sr uW) were evaluated for each 
experiment and treatment group using elliptical regions of interest in Living Image 
Software (Perkin Elmer). Fluorescent signal for Alexa Fluor 647-NP LN drainage was 
normalized to the fluorescent signal measured at the site of injection. 
4.2.4 Use of animals 
All animal procedures were performed with Institutional Animal Care and Use 
Committee (IACUC) approval and animals were housed in a central animal facility at 
Georgia Institute of Technology. 
4.2.5 Quantification of NP LN accumulation 
To determine the amount of NP accumulated in draining LN, either fluorescence 
quantification of fluorescently labeled NP[10, 104] or a modified assay measuring PEG 
using Iodine and barium chloride, which form a barium-iodide complex of the glycol, 
was performed.[166, 167] For the fluorescent quantification of percent of injection, LN 
homogenate was taken and read at 655/675 nm, and the concentration of 
Alexa Fluor 647-NP was determined using a standard curve of Alexa Fluor 647-NP that 
was allowed to react at 37°C for 24 h. For the iodine PEG assay centrifuged LN 
homogenate, BaCl solution in 1N HCL, and KI solution supplemented were reacted. The 
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absorbance was measured at 535 nm, and the concentration of NP was determined using 
a standard curve of NP diluted in 1x PBS. 




 concentration using modified Saville, 
Griess, and coumarin boronic acid assays 
The Saville and Griess assays, which work on the principle of a two-step 
diazotization reaction between a sulfanilamide-based diazonium ion, formed from nitrite 
under acidic conditions, coupled with N-(1-naphthyl)ethylenediamine dihydrochloride 
(NEDD), were performed as previously described.[13] Briefly, sample solution (NO 
donor, tissue homogenate, or plasma) was mixed with either sulfanilamide solution or 
mercuric chloride solution prior to mixing these solutions with NEDD or 0.4N HCl. 
Absorbance was read at 540 nm and the difference between mercuric chloride and 
sulfanilamide solutions and the difference between sulfanilamide solution with and 
without NEDD taken as the SNO and NO2
-
 signals, respectively. SNO and free NO2
-
 
concentrations were calculated using a standard curve of S-nitroso-beta-mercaptosuccinic 
acid. Sample peroxynitrite (ONOO
-
) was measured using a 1:1 mixture with 100 mM 
coumarin boronic acid (Cayman Chemical) (10 mg/mL in Dimethylformamide (DMF) 
diluted in 1x PBS), which works to identify ONOO
-
 through oxidation by ONOO- to the 
fluorescent probe coumarin in a stoichiometric fashion, or PBS to determine tissue 
background and fluorescence measured at 370/455 nm after 15 min of reaction (short 
time to limit possible measurement of hydrogen peroxide, which occurs at a much slower 
rate) ONOO
-
 was calculated using a standard curve of ONOO
-
 solution (Cayman 
Chemical) in 0.3N NaOH. 
4.2.7 SNO release studies 
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SNO-NP solutions in 1x PBS were incubated in closed vessels at 37°C and SNO 
concentrations monitored over 72 h using the Saville assay. 
4.2.8 In vivo SNO LN delivery time course studies 
C57BL/6J mice were injected intradermally in the forelimbs with 30 µL of 
treatment solution. The animals were maintained under isoflurane anesthesia for the 
duration of the injection. At the indicated times post-injection, animals were anesthetized 
using isoflurane and blood harvested by cardiac puncture using a 27-guage needle and 1 
mL syringe prefilled with 15 µL 50 mM ethylenediaminetetraacetic (EDTA). The blood 
was transferred to a microvette tube containing K4EDTA (microvette) and stored on ice 
until analysis (<1 h). Animals were then sacrificed by cervical dislocation and tissues, 
including LN, spleen, kidneys, and liver, were separately harvested, homogenized and 
weighed in preweighed tubes containing zirconium beads and 450 µL 13 PBS as 
previously described.[163, 164] Plasma was prepared from whole blood by  
centrifugation at 2000 g for 10 min, transferring the plasma layer into a microtube and 
retaining the supernatant. The homogenates (other than those prepared from harvested 
LN) were diluted lower to 5 wt/wt% in 1x PBS to reduce background for the Saville and 
Griess assays.[60, 168-170] All homogenate solutions were subsequently centrifuged at 
10,000 g for 20 min and supernatants transferred for determination of SNO, NO2
-
 , and 
ONOO
-
 concentrations using the Saville, Griess, and coumarin boronic acid assays, 
respectively, described above. 
4.2.9 Flow cytometry 
Mice were injected with SNO treatment group either with or without 
Alexa Fluor 647 labeling. Twenty-four hours later the mice were sacrificed and both LN 
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from the same injection side of the animal were placed in 900 µL PBS on ice in the dark. 
One hundred microliters of 10 mg/mL Collagenase (Roche) solution in PBS was added to 
each LN well and incubated for 1 h at 37°C. LN were then gently separated through a 
70 mm cell strainer into 50 mL conical tubes using a 1 mL syringe plunger. Ten 
milliliters PBS was added to push cells through and then the cells were spun down at 
300 g for 5 min. The cells were counted and then plated in their entirety into a round 
bottom 96-well plate. The cells were stained with 100 µL of 2.4G2 solution, followed by 
Zombie Aqua Live/Dead (Biolegend) solution, and then finally monoclonal anti-mouse 
mAb (Biolegend) (BV411 CDllc; BV650 B220; BV711 CD3; PE CD169; AF700 
CD11b). Data was acquired in a LSRFortessa (BD Biosciences) flow cytometer with 
compensation using either calibration beads (Thermo Fisher) or single-stained cells. Data 
analysis was performed using FlowJo software (FlowJo). 
4.2.10  Histology 
Two percent paraformaldehyde fixed forelimbs were paraffin embedded, sliced to 
10 μm thickness, decalcified, and stained with hematoxylin and eosin. The slices were 
imaged using a Hamamatsu Nanozoomer. 
4.2.11 Statistical analysis 
Data are expressed as mean6standard error of the mean. Statistical analysis was 
performed using Prism 6. Statistical significance was defined as p ≤ 0.05. 
4.3 Results 
4.3.1 SNO-NP characterization 
We previously described an NO-donating NP formulation[13] based on the 
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formation of SNO within oxidation-sensitive poly(propylene sulfide)-core, pluronic block 
copolymer corona NP.[94, 108] These NP are sufficiently small (approximately 30 nm in 
diameter for optimum lymphatic uptake[9, 11, 67, 163, 164] to be taken up into 
lymphatic vessels and passively transported to the draining LN[10, 67, 104] over the 
course of several days after injection (Figure 4.1b,c) proportional to the administered NP 
dose (Figure 4.1d) 
 
Figure 4.1: NO delivery to lymphatic tissues using lymphatic-draining NPs. a) By 
virtue of their blood impermeability that prolongs their retention at the site of 
injection, hydrodynamically large drug delivery vehicles such as 30 nm 
lymphatic-draining NP have enhanced lymphatic uptake relative to small molecules, 
which can be leveraged to enhance LN delivery of encapsulated NO. Representative 
IVIS images (b) and quantification (c) of Alexa Fluor 647-labeled NP transport from 
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the site of injection (white arrows) in the forearm skin to the draining ipsilateral 
(closed line) axillary and brachial LN (dLN) but not nondraining contralateral 
(dashed line) LN (non-dLN) after 24 h. n=6 samples per group. d) NP drain to LN 
from the site of injection in a manner proportional to the starting concentration of 
injected NP. **p<0.01.[149] 
In this NP formulation, the high concentration of free thiols in the hydrophobic 
NP core allows for efficient and rapid loading of NO through the formation of SNO 
(Figure 4.2a). This reaction occurs very quickly and reaches peak efficiency, as 
determined by the concentration of SNO measured compared to the total NP thiol 
concentration, between 10 and 20 min of reaction time (Figure 4.2b). SNO formation is 
also most efficient when the acidified nitrite is between 2 and 4 equivalents of NP free 
thiol (Figure 4.2c,d), likely due to the process of high concentrations of nitrite converting 
to a nitrosating species in low pH resulting in several side reactions occurring between 
the acidified nitrosating species and SNO formed[23, 171] that often cause the SNO 
decomposition. Formation of SNO-NP does not alter NP hydrodynamic size (Figure 
4.2e), which can be synthesized to a range based on the pluronic-to-propylene sulfide 
monomer ratio used,[114] nor polydispersity (data not shown), indicating that the acidic 
nitrosating conditions do not affect the Pluronic critical micelle concentration nor 
promote degradation of the stabilizing core disulfide bonds. To ensure that the loaded NO 
will maintain its stability in the NP over time and as dilution occurs, as well as the 
capacity of multiple SNO doses to be utilized in a controlled manner, we tested the 
degradation of the SNO from SNO-NP at 37°C. SNO-NP were diluted to one of three 
concentrations: 10, 5, and 1 mM. SNO decay from SNO-NP was steady over the entire 
72 h for each tested dilution (Figure 4.2f) and the decay half-life was insensitive to 
starting SNO concentration (Figure 4.2g), indicating that as the SNO-NP concentration 
changes in vivo the release profile of NO is not significantly altered. 
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Figure 4.2: Synthesis and characterization of S-nitrosothiol poly(propylene sulfide) 
NPs (SNO-NP). a) Schematic of micellar structure of pluronicstabilized, 
poly(propylene sulfide) NP containing free core thiols that become S-nitrosated 
using an acidified sodium nitrite protocol at room temperature. SNO on the SNO-
NP can either be retained on the NP or can be transnitrosated to a low molecular 
weight thiol (LMW-SH); NO that is released from the SNO-NP will be either 
oxidized with oxygen to nitrite, or will interact with superoxide and form 
peroxynitrite. b) Efficiency of S-nitrosation reaction, defined as the amount of S-
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nitrosothiol that can be generated per amount of starting free thiol concentration, 
reaches a maximum around 15 min. c) Efficiency of S-nitrosation reaches a 
maximum at 2–4 eq. sodium nitrite to free core thiols. d) Low pH is required for the 
S-nitrosation reaction with sodium nitrite and free core thiols. e) SNO-NP are stable 
and the same size as unmodified NP, indicating that the Pluronic-stabilized, 
poly(propylene sulfide) NP structure remains stable under these conditions. f) SNO 
decay from SNO-NP at different starting SNO concentrations over 3 days. g) The 
approximately 50 h half-life of the SNO release from SNO-NP is constant at 37°C 
regardless of starting SNO concentration. n=3 samples per group.[149] 
4.3.2 In vivo NO donation 
We next implemented a well described intradermal forearm lymphatic delivery 
model, whose lymphatic network efficiently drains to the ipsilateral axillary and brachial 
LN (Figures 4.1b and 4.3a),[10] to assess the delivery and retention of NO delivered 
through SNO-NP or standard small molecule SNAP. Whole animal imaging of NP and 
NO probe DAF-FM DA (mixed 1:1 with HgCl II), fluorescence 24 h post-injection 
revealed that only SNO-NP, which accumulated within LN draining the site of 
intradermal injection (Figure 4.3 a,b), and not SNAP resulted in appreciable LN NO 
signal (Figure 4.3c,d). 
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Figure 4.3: Colocalization of NO and SNO-NP fluorescence in LN draining site of 
injection demonstrates NP-mediated lymphatic transport facilitates NO delivery to 
LN. Representative IVIS images (a, c) and quantification (b, d) of Alexa Fluor 647 
(a, b) and NO probe DAF-FM DA (c, d) fluorescence in draining LN associated with 
SNO-NP, but not SNAP administration in the forelimb skin. White arrow, 
intradermal site of treatment group injection; white circle, LN draining the site of 
intradermal injection; yellow circle, DAF-FM DA injected LN.[149] 
Next, using the absorbance-based assays of Saville and Griess to measure RNS 
within harvested, homogenized tissues through endpoint analysis, we found that 
following intradermal administration of SNO-NP or SNAP loaded with 20 mM SNO, that 
SNO was only significantly elevated in the LN over the course of 72 h post-injection 
relative to control (saline injected) animals when delivered through the SNONP (Figure 
4.4a). These results are consistent with our image-based detection of LN-delivered NO 
(Figure 4.3) and confirm our hypothesis that small molecule NO donors are not 
sufficiently transported to the LN, requiring, instead, lymphatic-draining NP that can be 





, RNS implicated in NO bioactivity[122] and cytotoxicity,[172, 173] respectively, 
were detected at levels above background for any assayed time post-injection with either 
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NO donor (Figure 4.4b,c). As the result of SNO-NP, SNO levels in plasma were elevated 
1 h post-injection, but returned to near baseline (saline) by 24 h post-injection (Figure 
4.4d). SNAP, on the other hand, resulted in a higher but not statistically significant 
different plasma SNO concentration relative to saline-control-treated animals over the 
course of the experiment (Figure 4.4d), most likely owing to a constant clearance from 




 levels compared 
to saline controls were measured over the time course of experimentation (Figure 4.4e,f). 
RNS levels in the spleen, kidneys, and liver remained unchanged relative to saline 
controls over the course of the experiment for both NO donor treatment groups, except in 
the case of the liver where there was a small increase in ONOO
-
 measured in animals 
treated with either NO donor (Figure 4.4h). Within draining lymph node (dLN), however, 
SNO levels above those in saline-treated animals were found to be elevated 100-fold for 
SNO-NP- relative to SNAP-treated animals (Figure 4.4g). ONOO
-
 exposure was also 





 concentrations were elevated in plasma, whereas SNO levels increased, with 
SNO-NP and SNAP treatment differing approximately twofold, but not to statistically 
significant levels (Figure 4.4i). 
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Figure 4.4: SNO-NP improve delivery of SNO to LNs draining the site of 
intradermal injection compared to small molecule NO donor. a) SNO-NP showed 
improved delivery and retention over 72 h of SNO to LN compared to SNAP. * 
indicates statistically greater SNO for SNO-NP compared to SNAP. b) No 
appreciable accumulation of nitrite within LN for either SNO-NP or SNAP 
compared to control. SNO-NP and SNAP signals were not detectable (ND) at 1 or 72 
h. c) No appreciable accumulation of peroxynitrite within LN for either SNO-NP or 
SNAP compared to control. d) SNO-NP showed early spike in SNO concentration 
within plasma, whereas SNAP peaks at 24 h. PBS and SNAP signals were ND at 72 
h. ** indicates statistically greater SNO for SNO-NP compared to SNAP. e) No 
appreciable accumulation of nitrite within plasma for either SNO-NP or SNAP 
compared to control. SNO-NP and SNAP signals were ND at 24 and 72 h. f) No 
appreciable accumulation of peroxynitrite within plasma for either SNO-NP or 
SNAP compared to control. g) SNO-NP showed greater bias of SNO delivery 
compared to SNAP to LN than to plasma. Levels of SNO accumulation in the 
spleen, kidney, and liver were ND. h) There was a modest accumulation of 
peroxynitrite in the LN for SNAP but not SNO-NP, whereas in the liver there was a 
larger, but not statistically significant, difference in accumulation of peroxynitrite in 
the liver. The accumulation of peroxynitrite in the spleen and kidney was ND for all 
groups. i) In the plasma there was a noticeable but not statistically significant 
difference in the area under the curve (AUC) of SNO signal for SNO-NP vs. SNAP. 
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g–i) PBS AUC was subtracted from SNO-NP or SNAP AUC. For all graphs the 
columns/points and error bars represent the mean + SEM (n=3–6 samples per 
group). *p<0.05, **p<0.01.[149] 
The capacity of SNO-NP to control the level of NO delivered to lymphatic tissues 
was next evaluated in an in vivo dosing study. SNO dilutions were created through simple 
dilution of SNO-NP solution or when SNO-NP were formed from NP of differing thiol 
levels (Figure 4.5a). We found total dLN SNO (Figure 4.5b) but not NO2
-
 (Figure 4.5c) 
levels generated as a result of SNO-NP treatment 24 h post-injection were proportional to 
the concentration of total SNO administered, irrespective of how the SNO dilutions were 
generated. Levels of both SNO and NO2
-
 in plasma were either not detectable or not 
statistically higher than saline controls (data not shown), save the highest tested dose of 
SNO-NP, 20 mM. Suggesting corresponding biological effects on lymphatic tissues, LN 
draining the site of injection also increased in size proportionally to administered NO 
amount (Figure 4.5d); an effect attributed to the bioactive SNO since delivery of 




Figure 4.5: SNO-NP can be synthesized to deliver a wide range of SNO doses that 
accumulate within the dLN in a manner proportional to concentration. a) The SNO 
concentration of SNO-NP can be modified by either diluting maximally nitrosated 
SNO-NP with a high starting SNO concentration, or by synthesizing SNO-NP with 
different initiator concentrations such that the maximal nitrosation results in 
differing SNO concentrations due to the altered free thiol concentration. b) The 
total SNO within the dLN at 24 h is proportional to the amount of SNO delivered by 
SNO-NP either by dilution or by dose-matched NP batches with different initiator 
concentrations. c) Total nitrite within the dLN at 24 h was relatively insensitive to 
starting SNO concentration of SNO-NP. d) The weight of dLN 24 h post-injection 
was increased slightly in proportion to the starting SNO concentration of SNO-NP. 
For all graphs the columns/points and error bars represent the mean + SEM (n=3–8 
samples per group).[149] 
4.3.3 SNO-NP effects on dLN-resident cell viability, abundance, and NP uptake 
We next sought to begin to elucidate the effect of NO delivery to LN on resident 
cells. First, the viability of total (Figure 4.6a), CD451 (immune) cell subtypes including 
lymphocytes (T and B cells, CD3+B220- and B220+CD3-CD11b-, respectively), 
conventional and plasmacytoid dendritic cells (CDC - CD11c+B220- and PDC - 
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CD11c+B220+, respectively), and medullary sinus macrophages (MSM): B220-CD3-
CD11b+CD11c+CD169+F4/80+; subcapsular sinus macrophages (SSM): B220-CD3-
CD11b+CD11c+CD169+F4/80-; medullary cord macrophages (MCM): B220-CD3-
CD11b+CD11c+CD169-F4/80+, respectively (Figure 4.6b) resident within dLN 24 h 
post-injection was found to remain unchanged by SNO-NP treatment relative to control 
animals, as well as treatment with plain NP and SNAP, as assessed by flow cytometry. 
Despite no significant changes in viability, the abundance of cells within LN draining the 
site of injection was dramatically increased by SNO-NP but not SNAP or plain NP 
treatment; in particular T and B lymphocytes were more abundant, as well as both 
conventional and plasmacytoid dendritic cells and MCM subtypes, albeit for the later 
three cell types not to a statistically significant extent (Figure 4.6c). However, the 
proportionality of LN-resident CD45+ cell subpopulations remained approximately 
equivalent (data not shown). Notably, while the frequency of total LN-resident cells that 
took up or were associated with NP 24 h post-injection was somewhat reduced for 
SNO-NP- relative to NP-treated animals, the total number was negligibly affected by 
NP-mediated SNO delivery to LN (Figure 4.6d). SNO delivery resulted in NP associating 
to higher extents with CDC, PDC, and MCM (Figure 4.6e), and at diminished 
frequencies with LN-resident T and B cells (Figure 4.6f). 
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Figure 4.6: SNO delivery by SNO-NP does not negatively affect the viability but 
increases the number of cells resident within LNs draining the site of intradermal 
injection, resulting in modestly altered distributions of cellular NP accumulation. a) 
SNO delivery from SNO-NP did not affect the viability of dLN cells compared to 
small molecule NO donor SNAP, plain NP, or PBS control. b) SNO delivery from 
SNO-NP did not alter the viability of any specific cell subtype within the LN 
compared to other groups. c) SNO delivery from SNO-NP resulted in increased 
numbers of B and T cells relative to SNAP, plain NP, and PBS control. While SNO 
delivery from SNO-NP also resulted in increased numbers of other cell types, the 
results were not statistically significant. d) SNO delivery from SNO-NP resulted in a 
reduction in both the number and percentage of NP positive cells. e) SNO delivered 
from SNO-NP resulted in an increased number of NP positive dendritic and 
macrophage cells while showing a slight reduction in the number of NP positive B 
and T cells compared to plain NP control. f) SNO delivered from SNO-NP did not 
affect the percentage of NP positive dendritic and macrophage cells, but did result 
in a drastic reduction in the percentage of NP positive B and T cells compared to 
plain NP control. Cells were gated as follows: B cells – B220+CD3-CD11b-; T cells – 
CD3+B220-; conventional dendritic cells (CDCs) – CD11c+B220-; plasmacytoid 
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dendritic cells (PDCs) – CD11c+B220+; subcapsular sinus macrophages (SSM) – 
B220-CD3-CD11b+CD11c+CD169+F4/80-; medullary sinus macrophages (MSM) - 
B220-CD3-CD11b+CD11c+CD169+F4/80+; and medullary cord macrophages 
(MCM) - B220-CD3-CD11b+CD11c+CD169-F4/80+. For all graphs the 
columns/points and error bars represent the mean + SEM (n=3–6 samples per 
group). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, not significant.[149] 
4.3.4 Locoregional vs. systemic NO donation-associated inflammation and toxicity 
 Given NO’s pleiotropic and potential cytotoxic effects,[29, 35, 174] local and 
systemic markers of inflammation associated with NO donor treatment were assessed. 
Histological analysis of paraffin fixed slices of treated forelimbs revealed no apparent 
morphological changes in skin quality, thickness, or granularity for either NO donor 
treatment at 20 mM administered dose compared to saline control (Figure 4.7a). Despite 
increases in LN size associated with SNO-NP, but not SNAP, treatment, spleens of 
treated animals remained unchanged in gross size[102, 175] relative to control-treated 
animals 24 h post-injection (Figure 4.7b). Levels of plasma alanine transaminase (ALT) 
and aspartate transaminase (AST), markers of liver toxicity,[176] similarly were 
unchanged at all analyzed times post-injection (Figure 4.7c). 
 
Figure 4.7: Intradermal administration of SNO-NP does not result in local or 
systemic inflammation. a) Representative images of the inflammation reveal no 
qualitative difference in skin thickness or cellularity between groups. Red bar, 1 
mm. b) Top, representative spleen images from treated mice. Scale bar, 0.5 cm. 
Bottom, spleen sizes were found to not be statistically significantly different between 
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groups measured after 24 h treatment. c) There was no statistically significant 
difference in time-matched alanine transaminase (ALT) or aspartate transaminase 
(AST) measurements from the plasma over a 72 h time course between groups. n=3–
7. ns, not significant.[149] 
4.3.5 SNO-NP effects on lymphatic transport 
 With evidence of SNO-NP enhancing the efficiency of SNO delivery to LN 
compared to small molecule NO donor SNAP, we sought to determine how changing the 
dose of SNO delivered would affect the overall lymphatic transport to draining LN, as 
NO is known to affect lymphatic pumping function.[24, 25] As a metric of lymphatic 
transport function, total delivered amount of NP to LN was quantitatively assessed by 
endpoint analysis using an iodine-based absorbance assay on homogenized tissues, which 
overcomes the significant sensitivity limitations of whole animal imaging. NP 
accumulation within dLN was sustained, with a steep increase from the time of injection 
to 1 to 24 h followed by a slower and smaller increase from 24 to 72 h (Figure 4.8a). 
Furthermore, over the range of SNO concentrations tested (6–20 mM), NP accumulation 
within LN draining the site of injection was only modestly diminished and in a dose-
independent manner 24 h post-injection (Figure 4.8b).  
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Figure 4.8: SNO-NP efficiently drain to the LN and cause only a modest diminution 
in total NP LN accumulation. a) SNO-NP drained to and accumulated in the LN 
over 72 h as measured by iodine PEG stain assay. b) There was no statistically 
significant difference in the percent of injection of SNO-NP solution when the dose 
of SNO was altered, however, compared to plain NP the presence of SNO modestly 
attenuated the overall accumulation of Alexa Fluor 647-labeled NP in LN 24 h 
postinjection as measured by fluorescence. For all graphs the columns/points and 
error bars represent the mean + SEM (n=3–8 samples per group). *p<0.05; 
**p<0.01; ns, not significant.[149] 
4.4 Discussion 
While there have been several examples of reformulation of NO donors to achieve 
improved pharmacokinetics and biodistribution, including improving circulation time 
through polyethylene glycol conjugation[72] and NO bioactivity through 
multivalency,[73] to our knowledge no attempts have been taken to create a NO donor 
specifically for targeting lymphatics.[74] Several examples exist of larger molecular 
weight NO donors including a 64-valency R-SNO dendrimer donor[73] and NO-
containing NP;[75-79] however, all of these approaches presumably remain insufficient 
for NO modulation within the lymphatics because such formulations are non-optimal for 
lymphatic uptake.[163] 
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In this work, we explored the in vivo NO donating capacity of a SNO-NP delivery 
vehicle we previously reported that exhibits controlled profiles of NO release in its 
bioactive form.[13] Rapidly (approximately 10–20 min) nitrosated at close to 100% 
efficiency at approximately 2–4 molar equivalents of acidified nitrite (Figure 4.2b–d), 
these SNO-NP leverage a NP formulation, that by virtue of their size (Figure 4.2e) 
exhibit superior in vivo targeting of lymphatic tissues relative to conventional drug 
formulations (Figure 4.1b–d).[10, 177] We found these SNO-NP, which have a SNO 
dose-independent half-life of two days, to exhibit sustained levels of accumulation within 
LN draining the site of intradermal injection (Figure 4.8b). As a result, SNO-NP 
significantly increase the delivered dose of SNO to LN draining the site of intradermal 
injection (Figure 4.4a), resulting in an approximately 100-fold increase relative to SNAP 
in levels of SNO exposure above PBS-treated animals over 72 h post-injection 
(Figure 4.4g). This was accompanied by only an increase in plasma SNO levels 1, but not 
24 or 72 h post-injection (Figure 4.4d), a modest (approximately twofold) and not 
statistically significant increase in total plasma SNO exposure (Figure 4.4i), and no 




 levels (Figure 4.4(b,c,e,f,h,i). These dose-dependent 
effects (Figure 4.5), which were consistent whether generated by SNO-NP dilution of 
changing the extent of nitrosation through NP formulation, demonstrate the selectivity of 
NO, and predominantly SNO, delivery to lymphatic tissues mediated by SNO-NP is 
tightly controllable. 
We expect much of the SNO measured over the time scales of this study to be 
SNO remaining on the SNO-NP due to its half-life and high starting concentration. We 
can also infer that SNAP, which we would expect to be cleared from the skin site of 
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injection within minutes and to not be able to transport efficiently to the LN due to its 
size (approximately 220 Da),[11, 163, 164] does not transnitrosate to an appreciable 
extent to any large molecular weight proteins such as albumin that are capable of better 
transporting to the LN[102, 178] due to the lack of increased SNO in LN draining SNAP-
injected skin tissues (Figure 4.4a). Contrast this with the increased plasma levels of SNO 
resulting from SNO-NP 1 h post-injection (Figure 4.4d). Because these 30 nm NP do not 
have efficient access to the blood vasculature[104, 163] they would be retained for 
prolonged times at the site of injection,[163, 164] and because we have previously 
reported their propensity to efficiently transnitrosate physiological thiols,[13] we 
hypothesize that this initial spike is due to rapid transnitrosation of intradermally present 
small molecule thiols (cysteine, e.g., which can be present in excess of 100 µM [148]). 
Second, this may explain the only modest and dose independent changes in levels of NP 
LN accumulation resulting from SNO- vs. plain NP (Figure 4.8a). Because it has been 
shown that attenuation of lymphatic function (characterized by an increase in diastolic 
diameter and a reduction in pumping frequency) occurs with application of exogenous 
NO,[31, 178, 179] it is plausible that NP accumulation within LN would be more 
dramatically attenuated at times post-injection longer than the 24 h assessed here when 
more NO has been released from SNO-NP (Figure 4.2f,g). Additionally bolstering these 
two hypotheses are the fact that NO production in the interstitial space is involved in 
alterations of the microcirculation[180] resulting in greater blood flow through increased 
vascular permeability[181] as well as increased arteriolar vessel dilation.[182] These 
observations, often associated with the tumor vasculature,[182] further explain the 1 hr 
plasma spike of SNO from SNO-NP as well as the reduction in LN accumulation of 
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SNO-NP, which likely results from a NO-mediated combination of increased vascular 
access of the SNO-NP as well as a reduction in lymphatic pumping function.  
Despite the highly reactive and potentially cytotoxic nature of NO, we observed 
histologically no signs of inflammation at the site of SNO-NP injection, as either changes 
in skin thickness or granularity (Figure 4.7a), which is in line with several studies 
reporting the lack of inflammatory effects from NO donors.[77, 183-189] Additionally, 
no increases in ONOO
-
 were detected in any assayed tissue (Figure 4.4c,f,i), spleen sizes 
remained unchanged (Figure 4.7b), and plasma alanine transaminase and aspartate 
transaminase levels remained unchanged relative to saline-treated animals (Figure 4.7c). 
We did observe, however, increases in LN size (Figure 4.5d) that were potentially 
explained by flow cytometry analysis revealing dramatic increases in resident immune 
cell frequencies (Figure 4.6c), an effect potentially arising from the influx of cells 
circulating in the blood[190] caused by LN-delivered SNO mediated by lymphatic-
draining NP. This is supported by measured frequencies of NP association with T and B 
cells dropping approximately 50% (Figure 4.6f) while total cell counts correspondingly 
increased approximately 30% (Figure 4.6c). Furthermore, the viability of LN-resident 
cells was not diminished by SNO-NP treatment (Figure 4.6a,b). Consistent with only 
modest decreases in total levels of NP accumulation within LN as a result of SNO 
delivery (Figure 4.8a), the extent of NP uptake by LN-resident cells remained similar 
(Figure 4.6d). However, SNO-NP did associate at increased levels with dendritic cell and 
MCM subtypes (Figure 4.6e) corresponding to the measured increases in abundance of 
these cell subtypes (Figure 4.6c), while the total frequency of NP-associated cells 
remained similar to plain NP indicating that these cells’ barrier/scavenger functions[84, 
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191, 192] were unperturbed by SNO delivery. On the other hand, T and B cell abundance 
similarly increased (Figure 4.6c), but total frequencies of NP-associated lymphocytes 
were nearly inversely reduced (Figure 4.6f), hinting that NO release did not alter access 
of SNO-NP to these cells and that the reduced frequency was due to a dilution effect. 
Taken together, these data indicate that delivery of SNO alone or in combination with 
co-encapsulated drug/agent to LN-resident cells in a manner roughly similar to those 
described for the plain (non-SNO containing) NP[177] may be efficiently and rapidly 
achieved also by SNO-NP, while retaining the LN- and cellular biodistribution benefits 
of NP delivery. Of note, cellular uptake of the SNO-NP should not inhibit the function of 
subsequently released NO, since transnitrosation within the cell to small molecule thiols, 
such as cysteine, can occur and intracellular NO-species can be extracellularly 
released.[193] Therefore, NP-delivered SNO, released as NO either extra- or 
intracellularly within LN, would presumably be bioactive. 
4.5 Conclusion 
In summary, we have demonstrated that SNO-NP facilitate the controlled and 
sustained delivery of SNO to lymphatic tissues in a preclinical in vivo mouse model, 
resulting in a two order of magnitude increase in the accumulation of SNO in the LN over 
the span of 72 h post-injection above control animals compared a dose-matched small 
molecule NO donor. Additionally, we found dramatic increases in the abundance of LN-
resident lymphocytes, dendritic cells, and MCM despite no apparent LN-resident cell 
death associated with treatment nor signs of systemic and injection site-localized toxicity 
after administration. Since NO has shown in vitro/in vivo promise with lymphatic-related 
cancer therapy and infectious disease applications but has been unable to progress due to 
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delivery-related challenges, with further development of this NO delivery technology has 
the significant potential to advance such NO-based therapeutic approaches through 




CHAPTER 5. Multi-stage Lymphatic Delivery System Augments 
Delivery to Lymph Node Paracortex Cells 
 
5.1 Introduction 
The targeting of LN, tissues where organized lymphocyte accumulation in the 
body occurs,[11, 194] has the potential to address a variety of unmet clinical needs 
including remedying pathologies such as B and T cell malignancies, HIV reservoirs in 
CD4 T cells, and sentinel LN metastasis[195-198], as well as improving vaccine 
responses[102] and promoting tolerance.[199] Delivery of drugs to the LN, however, is 
hampered by several delivery barriers, the primary one of which is achieving lymphatic 
uptake as LN are accessed by the lymphatics from the periphery following intradermal 
injection.[17, 67, 104, 200] Due to the structure and location of the lymphatics, molecules 
within a certain size range are taken up preferentially[11, 133] with molecules in the size 
range between 5 and 100 nm being shown to favorably drain following intradermal 
injection.[160-162]  
However, this size dynamic changes within the LN as the LN reticular network 
has been shown to restrict access of lymph-borne material to the cortical parenchyma, 
which is important in not only preserving the naïve state of the lymphocyte 
microenvironments, but also in protecting from a wide variety of immunogenic molecules 
that would adversely influence an immune response occurring within the cortex, such as 
microbes and their soluble products during microbial infections.[85] The efficiency of 
this barrier has been extensively shown to depend on the size of the lymph-borne 
molecules with high MW tracers all but virtually excluded from conduit and cortex 
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access by the subcapsular sinus.[83, 86-88] Conversely, low MW tracers experience 
graduated but not absolute exclusion, with molecules under 70 kDa having access to the 
conduits.[84, 85] However, permeation of these low MW molecules from the conduits to 
the lymphocytes within the paracortex is mostly restricted, indicating that for immune 
challenges with limited antigen concentration this might be a significant barrier, but with 
larger concentrations direct lymphocyte access could be possible and produce 
physiologically relevant results.  
Due to this unique structure of the lymphatics and the partitioning of solutes 
within the LN reticular network, both of which are favor opposing size scales of 
molecules, there remains a significant technological gap. To achieve localized delivery to 
LN, principles of NP-mediated lymphatic targeting are often employed,[81, 104] with 
previously demonstrated in vivo success in tumor immunotherapy models.[10, 104, 107, 
201, 202] While the concept of spatiotemporal regulation of delivered cargo is not a new 
idea for tumor drug delivery,[103, 203, 204] its principles have yet to be broadly applied 
towards LN targeting.[205] This is most likely due to the limited number of modalities 
available for facilitating in vivo control over the release of cargo.[71] Therefore, systems 
that have shown utility in tumor drug delivery that rely on enzyme sensitivity or 
hydrolytic degradation will not be broadly applicable to LN targeting since LN do not 
normally possess large physiological deviations in soluble enzyme concentrations 
compared to their draining lymphatics making release of cargo not easily controllable. 
In this work, we have created an engineered NP system for enhanced lymphatic 
uptake and transport to the LN that can release its payload at different rates, thereby 
tuning the access of LN structures that are targeted, and the amount of cargo that is 
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released once in the lymphatics. Our approach consists of a two-stage system that 
combines 30 nm thiolated poly(propylene sulfide) NP[13, 114, 149] with orthogonally-
reactive OND linkers that degrade by a retro-Diels-Alder mechanism in a pH- and buffer-
insensitive manner at programmable half-lives ranging from hours to days to release 
small-molecule cargo.[206-208] We showed in vivo that the release of cargo within the 
dLN allowed for improved penetration into the deeper structures of the LN, and utilized 
our multi-stage NP system to improve immunotherapy for the treatment of cancer by 
delivering the TLR9 ligand CpG to treat LN lymphomas.  
5.2 Materials and Methods 
5.2.1 OND linker conjugation design 
Oxanorbornadiene linkers undergo relatively rapid Michael addition with thiols to 
produce adducts that fragment at predetermined rates by a retro-Diels-Alder mechanism. 
In previous work, we have identified a number of control elements that enable 
programmability of adduct half-lives by changing functional groups that are present on 
the OND. These functional group modifications vary in the strength of their effect on 
adduct stability, producing a range of adduct half-lives that can be tuned to meet the 
requirements of a given system.[206-208] For example: epoxidation of the electron-rich 
alkene produces thiol-reactive non-cleavable 5,6-epoxyoxanorbornenes, EONB 3, which 
is used as a control for OND fragmentation time. The synthesis of all electrophiles 1-5 
and 3-Me bearing model dye cargos used in this study is described in the supporting 
information.  
Fluorogenic Dansyl (Dn) Dn-modified OND 1-5 and 3-Me were reacted with free 
thiols on NP to determine their conjugation efficiency and reaction rate. Conjugation of 
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Dn-modified OND to NP was monitored by following the increase fluorescence emission 
(Ex: = 345 nm, Em: = 510 nm) over the course of the reaction.[208, 209] Reactions were 
performed at OND:thiol mole ratios ranging from 1:3.5 to 1:28, giving the average 
observed reaction rates for each of the OND variants. As expected, based on our previous 
work, OND derivatives exhibited somewhat different rates of conjugate addition. Second 




 were observed, with 1,4-dialkyl OND 1 
and trifluoromethylated 4 providing the slowest and fastest rates of addition, 
respectively.[206-209] However, the reaction rates of all OND were sufficiently fast such 
that loading of NP was achieved in under an hour at room temperature, demonstrating 
that this loading approach should be applicable to a wide variety of biological 
applications. Following conjugation of the OND to NP, the release rates of model 
Dn-furan cargo from the OND-Dn-NP conjugates were determined. This was achieved by 
dialyzing the OND-Dn-NP adducts at 37°C against PBS, and monitoring the fluorescence 
emission of the dialyzed sample at 510 nm over time. By following the loss of 
fluorescence from the dialyzed adduct solution, the fragmentation rates of OND-Dn-NP 
adducts were determined. The rapidly fragmenting OND 1 presented a challenge since 
the dialysis rate of free cargo was on a similar time scale as the fragmentation of adducts 
of this derivative. In order to accurately capture the fragmentation rate of adducts of 1, a 
solution of OND-1-NP was incubated at 37°C and small samples were periodically drawn 
and separated using size exclusion chromatography. The OND-1-NP fractions were 
collected and their fluorescence emission measured at 510 nm.  
The OND variants exhibited the predicted wide range of half-lives from 23 min for 
1, up to a nearly permanent linkage for 5. It is worth noting that in this NP-based delivery 
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system, we did not observe the expected decrease in adduct half-life for the 
N-methylsulfonamide derivative 3-Me relative to the parent secondary sulfonamide 3, as 
we have reported previously for small molecule and protein adducts.[208, 209] As a 
result, we explored derivative 2 to achieve release rates between those attainable with 
linkers 1 and 3. We rationalized that adducts of 5-alkyl-1,4-H,H 2 would behave in an 
analogous fashion to 1,4-unsubstituted OND dicarboxylates.[208] Conjugate addition 





). In contrast to 1-alkyl OND, which provide predominantly the 3-exo-syn 
Michael adducts, we observed two groups of products separable by chromatography on 
silica gel after reaction of 2 with beta-mercaptoethanol. 
5.2.2 Synthesis and characterization of OND derivatives 
A detailed description of materials, synthetic procedures and characterization data 
for new compounds is described elsewhere.[207, 208] In general, OND electrophiles are 
prepared by Diels-Alder reaction of substituted furans (1 eq.) and a slight excess (1.3 eq.) 
of the appropriate electron-deficient acetylene in minimal solvent at 60°C. 
Dansyl-modified ONDs 1, 3, 4, and 3-Me were synthesized according to methods 
described previously and have been characterized elsewhere.[208, 209] With the 
exception of 5-Dn, all Dn-modified ONDs were prepared by Diels-Alder reactions 
between electron deficient acetylenes and N-dansyl(methylfurfuryl)amine derivatives. In 
the case of 5-Dn, epoxidation of a t-butyl-carbamate protected OND to form the 
epoxyoxanorbornene EONB preceded installation of the Dn group to avoid oxidation of 
the fluorophore. For rhodamine (Rhod)-, FITC-, and coumarin (Coum)-modified 
electrophiles, conjugation of xanthene and coumarin dyes was performed after the 
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formation of OND-electrophiles using amide coupling and copper-catalyzed azide-alkyne 
“click” chemistry, respectively. See supporting information for synthetic schemes and 
details. 
5.2.3 Synthesis of OND-NP 
Nanoparticles were synthesized as previously described.[13, 134, 149] Briefly, 500 
mg of Pluronic F127 (Sigma-Aldrich, St. Louis, MO, USA, P2443) was added to 10 mL 
of degassed Milli-Q water, allowed to dissolve for 30 min with stirring, and was again 
degassed. To this solution, 400 μL of propylene sulfide (Sigma-Aldrich, P53209) was 
added under Argon and stirred for 30 min. Initiator weighing 28.8 mg (7.4 mM) was 
reacted with 322 μL of sodium methoxide (Sigma-Aldrich, 156256) and then added under 
Ar. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) (Sigma-Aldrich, 139009) was added 
under Ar to the solution 15 min later and the entire reaction stirred for 24 h. After 24 h 
the solution was exposed to air for 2 h and subsequently dialyzed for three days against 
4x5 L of Milli-Q water using a 100,000 Da molecular weight cut off cellulose membrane 
dialysis tubing (Spectrum Lab., Rancho Dominguez, CA, USA, 131414). NP size was 
measured by dynamic light scattering. Ellman’s assay (Thermo Scientific, Rockford, IL, 
USA, 22582) was used to determine the concentration of NP free thiols. NP were turned 
into OND-NP conjugates by reacting OND with excess NP in buffer at pH 7.4 for 1 h. 
For OND-Dn variants, fluorescence was only present after conjugation and no further 
purification was required. For OND variants bearing Rhod, FITC, and Coum cargos, due 
to the non-fluorogenic nature of these OND derivatives and incomplete conjugation, 
purification was performed via PD-10 column chromatography (GE Healthcare, 
Pittsburg, PA, USA, 17-0851-01) followed by concentration with 10,000 Da spin filters 
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(Millipore, Bedford, MA, USA, 42407) to achieve pure OND-NP adducts at the original 
NP concentration. 
5.2.4 Synthesis and preparation of OND-CpG-NP 
CpG-B-NH2-3’ 1826 (5′-TCCATGACGTTCCTGACGTT-3’-(CH2)3-NH2) was 
purchased from Eurofins Genomics on the 1 μmol scale. SPO3-CpG-B 1826 (5′-
TCCATGACGTTCCTGACGTT-3’-SPO3) (PTO-CpG) was purchased from Microsynth 
on the 1 μmol scale. The 5’ was chosen for modification with phosphothioate, while the 
3’ was chosen for modification with amine because the CpG can tolerate greater 
modification to the 3’ end and still maintain immunostimulatory potency.[210] 
OND-3-CpG (OND-CpG) was installed on the CpG 3’ using EDC/NHS; the OND-CpG 
was purified using precipitation with glycogen. PDS-NP were synthesized as previously 
reported.[134] PDS-NP were thiol-activated by adding Dithiothreitol (DTT) to 100 mM 
for 30 min. The solution was then cleaned of DTT on a PD-10 G25 column followed by 
collection of the NP fractions and then concentrated to 80-100 mg/mL with a 4 mL 
10 kDa Amincon Spin filter at 4000 x g for 30 min and 15 min. The concentrated NP 
solution was then run on three 5 mL 7 kDa Zeba spin columns at 1000 x g for 2 min in 1x 
-/- PBS. OND-CpG was added to the NP solution at a concentration of 1 ug/15 µL NP 
(80 mg/mL) and reacted for 12 h. Following reaction the solution was run on a Sepharose 
CL6B column 1x30 cm. The fractions were assayed for NP using Iodine[167] and Gel 
Red for CpG.[10] The OND-CpG-NP conjugate fractions were pooled and concentrated 
with a 10 kDa Amicon Spin filter at 4000 x g for 30 min. Final concentration of CpG was 
determined using Gel Red and Iodine standard curves for CpG and NP, respectively; the 
average concentration of CpG was between 0.4-0.8 ug CpG/30µL NP (40 mg/mL). For 
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PTO-CpG-NP, PTO-CpG was added to PDS-NP at a concentration of 1 ug/15 µL NP 
(40 mg/mL) and reacted 12 h. The solution was separated using column chromatography. 
5.2.5 Characterization of OND-Dn-NP conjugation and fragmentation rates 
Oxanorbornadiene conjugation rates to NP were determined using OND-Dn 
variants due to their fluorogenic nature. The Dn fluorescence is quenched by the OND 
electrophile presumably by a photoinduced electron transfer mechanism, and a robust 
fluorescence is observed following conjugate addition.[208, 209] OND were added at 25, 
50, 100, and 200 µM to NP with a thiol concentration of 700 µM (550 µM thiol was used 
in reactions with 2), yielding a mole range of OND to thiol ratios of 1:3.5 to 1:28 in pH 
7.4 phosphate buffered saline. Fluorescence was tracked over the course of conjugation 
until a plateau was reached. The observed rate constant was determined by fitting to the 
linear form of the integrated second order rate equation. Fragmentation studies were 
conducted using dialysis membrane cups of 20,000 MWCO that retain the OND-Dn-NP 
adduct, but allow for the removal of fragmented OND dye cargo. OND-dansyl variants 
were reacted in buffer at pH 7.4 with excess NP for 1 h and then transferred to 20,000 
MWCO dialysis membrane cups at 37°C. Samples of 4x2 μL were extracted to minimize 
reduction of dialysate volume throughout the experiment and read for fluorescence at 
510 nm using a BioTek Synergy H4 Multi-Mode Microplate Reader. Size-exclusion 
chromatography on a PD-10 column was employed for 1 because the adduct half-life for 
this linker is only 23 min and is similar to the rate of dialysis of free dansyl-furan. 
Samples were prepared using the staggered start method every 10 min for 2 h and 
incubated at 37°C. 
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5.2.6 In vitro collagen hydrogel penetration 
Collagen hydrogels at 7.5 mg/mL at physiological pH were prepared as reported 
elsewhere.[103, 211] Briefly, 144 μL of 8.63 mg/mL bovine collagen was mixed with 
3.7 μL of 1N NaOH and 19.2 μL of 0.17M EDTA. The collagen solution was drawn into 
100 μm capillary tubes (World Precision Instruments, Inc., Sarasota, FL, USA, 1B100-3) 
and then gelled for 24 h at 37°C. Fluorescein-labeled NP were conjugated to two OND 
derivatives with different dye cargo (and coumarin), purified and concentrated as 
described above, and then added to the collagen gel using a 31-gauge syringe. 
Fluorescence images were taken over the course of 12 h at 37°C using a Zeiss Axio 
Observer XLmulti S1 to measure the penetration of OND cargo relative to NP. 
Fluorescein-labeled NP were measured on the GFP channel, 3-Rhod was measured on the 
RHOD channel, and 1 Coum was measured on the DAPI channel. 16-bit grey scale 
intensity profiles were drawn from the loaded OND-NP solution through the length of the 
gel. 
5.2.7 In vivo experiments 
All animal studies were approved by and adhered to guidelines set forth by the 
Georgia Institute of Technology IACUC. 
5.2.8 Accumulation and multi-off rate studies 
In order to determine which OND linker would be most useful in vivo we 
conducted area under the curve studies over 72 h. Using our mouse forearm injection 
model 30 μL of OND-Dn-NP solution was injected under isofluorane anesthesia 
intradermally into both forearms of 6-week-old female C57BL6/J mice. The mice were 
allowed to recover for 24 h before being sacrificed and having axillary and brachial LN 
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excised and homogenized in 400 μL of DMSO to improve the weak fluorescence signal 
of dansyl furan in aqueous buffer. Using a standard curve generated in PBS we were able 
to calculate the percent injection at each time point for each OND linker within the LN 
homogenate. Using the measured half-lives we were able to calculate the percent of cargo 
that would be free at 24 h for each OND linker.  
In order to demonstrate the full advantage that different OND variants can 
provide, different mole ratios of OND derivatives 1, 3, and 4 were conjugated to the same 
NP solution such that the overall release rate of Dn-furan cargo would represent 
superposed simultaneous release profiles. For this study, OND 1, 3, and 4 were chosen 
for their greatly differing half-lives. These OND variants were mixed at mole ratios of 
8:1:1, 1:8:1, 1:1:8, and 1:1:1 of OND 1:3:4, and their conjugation was monitored by 
measuring fluorescence emission at 510 nm. The conjugation fluorescence (data not 
shown), demonstrated that the percent of total OND conjugated from each OND variant 
is directly proportional to its starting percentage, since the thiol from SH-NP are in 
excess. The fragmentation half-life for 1 is on the same time scale as that of the 
conjugation reaction, leaving approximately 50% of its conjugates intact by the time 
addition was completed, thereby limiting the final conjugated percentage of 1. Following 
conjugation, the OND-Dn-NP adduct solutions were incubated at 37°C and over the 
course of 28 h samples were drawn and separated on a size-exclusion column. The OND-
Dn-NP fraction eluting first was collected in bulk and its fluorescence emission at 
510 nm was measured. Only OND-Dn-NP-conjugated cargo elutes with the NP fraction, 
enabling the calculation of the percent of cargo still linked to the NP carrier, and the 
amount that has been released. Model release curves were created using the known 
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fragmentation rates of adducts of 1, 3, and 4 and the conjugation efficiency to predict the 
release profile for each of the OND variant ratios.  
As predicted by the model, incorporation of 1, which has a half-life of only 
23 min, led to an initial burst release of cargo and was observed for all ratios, but was 
most prevalent for the 8:1:1 mole ratio. When 4 was predominantly incorporated, there 
was a much slower overall release of cargo, since its half-life is 44 h, as observed for the 
1:1:8 mole ratio. The incorporation of 3, which has a half-life of 8.77 h at 37°C, lead to a 
steadier release observed over the time course of this experiment, particularly for the 
1:8:1 mole ratio. When all three OND variants were in an equimolar ratio (1:1:1), the 
release profile exhibited a steady release rate closely resembling that predicted by the 
model. The described results demonstrate the versatility and tunability of our OND-NP 
system for releasing cargo on a defined time scale. These results suggest that the rate of 
cargo release can be precisely tuned to target specific tissues along the NP delivery 
vehicle biodistribution route. Such a strategy could be powerful in improving LN 
delivery of small molecule cargo, where NP are used to facilitate lymphatic uptake and 
transport to the LN, while OND is used to specifically release cargo once lymphatic 
uptake has occurred, allowing the released cargo to diffuse deeply within the LN. 
5.2.9 IVIS imaging 
Fluorescent imaging was performed with an IVIS® Spectrum instrument 
(Perkin Elmer).[149] Animals were injected intradermally in the forearm with a solution 
of Alexa Fluor 647-NP or of OND 3-Rhod group either with or without Alexa Fluor 647 
labeling. Twenty-four h later the animals were sacrificed. To assess Alexa Fluor 647-NP 
drainage to LN, animals were imaged using Ex: 640, Em: 720 and an exposure of 0.1 s. 
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To assess 3-Rhod drainage to the LN, animals were imaged using a modified Rhodamine 
Red-X channel (Ex: 540, Em: 580) at an exposure of 0.1s. Total fluorescent counts and 
radiant efficiency (p/s·sr·μW) were evaluated for each experiment and treatment group 
using elliptical regions of interest in Living Image Software (Perkin Elmer). 
5.2.10 Confocal microscopy of LN penetration 
Alexa Fluor 647-labeled NP were conjugated to 3-Rhod, purified and 
concentrated, and then 30 μL was injected intradermally in the forearms of three 
6-week-old female C57BL6/J mice. After 24 h the mice were sacrificed and the axillary 
and brachial LN excised, cleaned under stereoscopic observation, and plated on a glass-
bottom 96-well plate for confocal imaging (Zeiss NLO 710). Using a 10x objective lens, 
16-bit fluorescence imaging was taken for Alexa Fluor 647 and rhodamine. Z-stacks 
approximately 6.4 μm in depth were taken through the depth of the LN (approx. 160 μm). 
In order to acquire the entire LN convex hull tiling was performed and the resulting 
images were stitched together. 
5.2.11 Measurement of NP vs. OND cargo distribution within LN images 
Lymph node images were taken on confocal as previously described. Z-stack 
images were converted to maximum intensity projections and then separated by 
fluorescence channel. Using a custom image J macro an outline was drawn around the 
LN boundary with the free from tool in the single channel images. The image was then 
thresholded to zero pixel value outside of the LN boundary and the custom script returned 
the coordinates of the outline and the thresholded fluorescence pixels within the LN 
boundary. Those coordinates were then transferred into a custom MatLab script that 
calculated and returned the binned minimum distance between the drawn LN boundary 
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and the thresholded fluorescent pixels. The collected data was gathered for 24 LN 
samples and the difference between the NP and 3-Rhod signals was calculated and 
normalized to determine the bias of fluorescence towards each species along distance 
from the LN border. 
5.2.12 In vivo immunotherapeutic tumor treatment 
Tumor treatment experiments were conducted by implanting 250K EL4 
lymphoma cells i.d. LN tumors were allowed to form over four days and then the mice 
were treated every day i.d. in the upstream forearm lymphatic drainage basin for five 
days with 0.75 µg of CpG in either OND, PTO, or free form. LN sizes were recorded at 
endpoint and assessed grossly with photographs. LN were frozen and sliced and stained 
with hematoxylin and eosin (HE) stain and assessed for tumor burden by histology. 
Primary tumor sizes were recorded and the tumor volume was modeled as an ellipsoid. 
5.2.13 In vivo functional CpG experiments 
30 µL of CpG in either OND, PTO, or free form (0.4-0.8 ug CpG) are injected i.d. 
into each forearm of a C57BL6 mouse under isoflurane anesthesia. After 24 h the mouse 
is sacrificed and the LN excised (axillary and brachial are pooled) and placed in 900 µL 
+/+ 1x PBS on ice. The cells are extracted from the LN as previously reported.[149] 
Briefly, 100 µL of 10 mg/mL Collagenase D is added and the LN are incubated for 1 h at 
37°C. The LN are then mechanically broken up on a 70 µm cell strainer and the 100 µL 
of cells are plated at a concentration of 10M/1mL. The cells are first blocked with 2.4G2, 
followed by Live/Dead staining, all staining (Live/Dead – BUV496, B220 – BV650, 
CD40 – FITC, CD45 – PerCP, CD86 – PE, MHCII – APC, CD11b – AF700, CD11c – 
APCeFluor 780), and then fixing in 2% PFA. Samples were run on a BD Fortessa. Cells 
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were gated according to the following markers: BC – CD45+ B220+ CD11c-; CDC – 
CD45+ B220- CD11c+; PDC – CD45+ B220+ CD11c+; Macrophage – CD45+ B220- 
CD11c- CD11b+; TC – CD45+ B220- CD11c- CD11b-. Maturation was gated according 
to the following markers: MHCII vs. CD40 or CD86. The plots were divided into six 
divisions: MHCII HI-CD40+, MHCII HI – CD40-, MHCII MID - CD40+, MHCII MID 
CD40-, MHCII LOW CD40+, and MHCII LOW CD40-. The same divisions were 
created for CD86. Reported markers were for MHCII MID CD40+/CD86+. 
5.2.14 Statistical analysis 
Statistical analysis: Data is expressed as mean ± standard error of the mean. 
Statistical analysis was performed using Prism 6. Statistical significance was defined as 
p ≤ 0.05. 
5.3 Results and Discussions 
5.3.1 Time-based intra-lymphatic release of cargo is achieved by OND-NP 
These NP possessed high concentrations of free thiols within the hydrophobic 
core or can be derivatized with modifications to the Pluronic F127 PEG groups allowing 
for the presence of free thiols on the PEG corona. OND linkers undergo relatively rapid 
Michael addition with NP thiols to produce adducts that fragment at predetermined rates 
by a retro-Diels-Alder mechanism (Figure 5.1a). These NP with either core thiols 
(SH-NP) or Pluronic thiols (PDS-NP) were 30 nm (Figure 5.1b,c) and showed fast 
conjugation with the OND linkers (Figure 5.2d), with very precise control over the 
fragmentation rate (Figure 5.1b) and release of cargo from the NP delivery vehicle 
(Figure 5.1e). In previous work, we have identified a number of control elements that 
enable programmability of adduct half-lives by changing functional groups that are 
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present on the OND. These functional group modifications (Figure 5.2a) vary in the 
strength of their effect on adduct stability, producing a range of adduct half-lives that can 
be tuned to meet the requirements of a given system (Figure 5.2b).[208, 209] The wide 
variety of half-lives, especially for adducts of 2, 3, and 4, which have half-lives of 2.77, 
8.77, and 44.2 h, respectively, provided an array of useful fragmentation times that could 
be harnessed for tuning cargo release for different in vivo applications.  
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Figure 5.1: Small molecule delivery to lymphatic tissues is enhanced using 30 nm 
lymphatic-draining NP. a) Poly(propylene sulfide) nanoparticles contain a large 
concentration of free thiols (SH) in their micelle core that can react through 
Michael-type addition with OND reagents, forming an OND-SH-NP-adduct. b) 
Representative TEM image of NP. Arrows indicate 30 nm NP. White bar indicates 
100 nm. c) Nanosight of PDS-NP and SH-NP showing 30 nm size. d) Conjugation 
rate of small molecule ONDs to SH-NP. e) Release curves of OND linkers 1-5 at 
37°C demonstrating that release of cargo from NP can be tuned by using different 
OND linkers. n>3 samples per group. f) Representative near infrared image 
showing NP transporting within mouse forearm lymphatic vessel (green arrow) to 
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draining LN (white circles). White arrow, site of intradermal injection. g) 
Representative IVIS image showing that 3-Rhod only transports to the dLN when 
conjugated through OND linkage to NP. h) Quantification of IVIS image 
demonstrating the presence of 3-Rhod signal and 647 signal from NP when 
conjugated by OND compared to the lack of 3-Rhod fluorescence when 
administered in free form. n=8 samples per group. i) Percent of injection 
accumulated in LN of total over time for different OND linker. j) Percent of free 
cargo divided by total percent of injection over time for different OND linkers. k) 
Area under the curve (AUC) of released OND cargo for different time periods: 1-4, 
4-24, and 24-72 h compared to half-life of OND linker. Peak LN accumulation AUC 
occurs with increasing linker half-life for later accumulation time periods. n=3 
samples per group.  
These NP have been previously shown in numerous studies to deliver 
immunomodulatory drugs as they drain efficiently through the lymphatics (Figure 5.1f) 
transporting small molecule drug to the dLN in high concentrations.[10, 104, 107] Using 
whole animal IVIS imaging following lymphatic uptake in our well described intradermal 
forearm lymphatic transport model, where the lymphatic network efficiently drains the 
intradermal injection to the ipsilateral axillary and brachial draining-LN (dLN)[10, 149], 
we found that 24 h post-injection small molecule dye was only measurable in the dLN 
delivered by OND conjugation to NP (OND-NP). We next assessed the effect of OND 
half-life on LN accumulation over a 72 h time course using end-point studies in our 
forearm lymphatic model, and observed that LN accumulation of tethered cargo 
depended on linker fragmentation half-life (Figure 5.1i), and optimization of this half-life 
allows for tuning of the percentage of free vs. bound cargo (Figure 5.1j) at various time 
points of the LN accumulation (Figure 5.1k). We ultimately settled on OND-3 to be our 
model linker given its moderate LN accumulation (Figure 5.1i) and its >85% released 
cargo at 24 h (Figure 5.1j) producing the highest area under the curve (AUC) of any 
linker between therapeutically relevant drainage times of 4-24 h (Figure 5.1k). 
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Figure 5.2: Based on the functional groups on the OND, retro-Diels-Alder 
fragmentation occurs at varying rates resulting in the release of furan-modified 
cargo and leaving a thiomaleate. Epoxidation of ONDs yields epoxyoxanorbornene 
(EONB) Michael acceptors that form adducts that are incapable of retro-Diels-
Alder fragmentation. Dyes with a range of emission wavelengths were selected as 
model cargos in this study. a) OND and EONB electrophiles and model fluorophore 
cargos presented in this study. By changing the substituent groups around the OND 
ring, different rates of retro-Diels Alder fragmentation were achieved. b) Table of 
rate constants and fragmentation half-lives for different Dn-OND conjugates. OND 
derivatives exhibited somewhat different rates of conjugate addition. Second order 
rate constants ranging between 5-61 M-1s-1 were observed, with 1,4-dialkyl OND 1 
and trifluoromethylated 4 providing the slowest and fastest rates of addition, 
respectively. 
5.3.2 OND-mediated release of cargo from OND-NP spatially biases cargo penetration 
both in vitro and in vivo 
To assess whether released cargo offered any advantages of penetrating the highly 
collagenous LN matrix, we turned to a previously published in vitro model looking at the 
diffusion of released OND cargo vs. the NP delivery vehicle in a collagen hydrogel.[103, 
211] Fluorophore variants of OND 1 and 3 were synthesized and conjugated to 
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Fluorescein-labeled NP. The OND-NP adduct was added to a model collagen hydrogel 
(at a concentration of collagen similar to that of a LN).[194] The diffusion of OND-NP 
and its released cargo into the collagen hydrogel was tracked with fluorescence 
microscopy over 12 h at 37°C using three fluorescence channels, one for the NP and one 
for each OND variant (Figure 5.3a, left). After 12 h of incubation, the penetration of the 
different cargos was vastly different from each other and from the NP delivery vehicle 
(Figure 5.3a, right). The short fragmentation half-life of 1 resulted in the farthest and 
fastest penetration compared to the slower release of cargo from adducts of 3 and the 
minimal penetration of the NP delivery vehicle. 
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Figure 5.3: In vitro and in vivo diffusion of released OND cargo. a) Left, 
Fluorescence images of FITC-labeled SH-NP, 1-Coum, and 3-Rhod at start of 
imaging in collagen hydrogel at 37°C. Insert, 2-photon image of collagen hydrogel. 
a) Right, Fluorescence images of FITC-labeled SH-NP, 1-Coum, and 3-Rhod at end 
of 12 h of imaging in collagen hydrogel at 37°C. White line, 1000 μm. b) Normalized 
intensity profile across field of view of 0 and 12 h time point for collagen diffusion 
experiment at 37°C. c) Normalized pixel value to 0 h time point for half-way point in 
field of view over course of 12 h diffusion experiment at 37°C. Data is from 
representative experiment with n = 2. Collagen hydrogel was formed at a 
concentration of 7.5 mg/mL. n=3 samples per group. d) Top, presence of NP and 3-
Rhod fluorescence at different Z stack depths of the LN. d) Bottom, Maximum 
intensity projection of LN. Left) 2-channel overlaid NP and OND cargo 
fluorescence. Middle) NP channel. Right) 3-Rhod channel. e) Difference in 
normalized pixel count for each single channel (NP vs. 3-Rhod) vs. distance from the 
outline (dashed white line). Negative shaded area indicates NP bias, vs. positive red 
shaded area indicating Rhod bias. n=24 samples per group. 
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By analyzing the penetration at different time points over the course of the 
experiment a more quantitative understanding of the impact of release time on cargo 
penetration was achieved. At the initial time point the penetration of each component was 
similar (Figure 5.3b, 0 h), with a small amount of cargo from 1 already beginning to 
penetrate the collagen matrix. Cargo released from 1 rapidly penetrated the collagen 
hydrogel by 4 h, while the slower cleaving 3 cargo more closely resembled the NP 
delivery vehicle at this time point (data not shown). By 12 h, 3 cargo had started to 
penetrate similarly to the earlier released cargo from 1, while the NP delivery vehicle still 
had minimal diffusion (Figure 5.3b, 12 h). When considering the arrival of dye at a deep 
point within the collagen hydrogel as would be the case for the LN subcapsular sinus, it 
can be seen that cargo from 1 arrived quickly, while cargo from the slower releasing 3 
arrived more slowly along with the NP delivery vehicle (Figure 5.3c, 0-5 h). However, at 
later time points, the NP delivery vehicle concentration at a deep point in the collagen 
matrix plateaued, indicating retarded migration of this species (Figure 5.3c, blue curve, 
5-12 h). In contrast, the 1 cargo concentration continued to increase in this time frame, 
indicating a greater mobility and enhanced penetration of the released cargo species 
(Figure 5.3c, yellow curve, 5-12 h). These results indicate that differential release of 
cargo based on time can have a dramatic effect on the ability of cargo to penetrate 
restricted tissue spaces. Within LN, these results portend that released cargo has a better 
ability to penetrate deeply into the LN compared to the large NP delivery vehicle.[85]  
To demonstrate the benefit of timed-release of cargo within the LN to achieve 
penetration and accumulation, we performed proof-of-concept in vivo studies assessing 
the spatial distribution and depth of where the released fluorescent cargo penetrated to 
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within the LN compared to the NP delivery vehicle. Small molecule dye rhodamine was 
conjugated to 647-labeled NP through OND 3 and injected intradermally in the mouse 
forearm as before. After 24 h, the axillary and brachial LN were excised, cleaned, and 
imaged using fluorescent and two-photon confocal microscopy. Z-stacks were taken up to 
a depth of 160 μm into the LN. We first observed that 3 released rhodamine were present 
at deeper slices of the LN than NP (Figure 5.3d), which was present mostly in the 
superficial slices (Figure 5.3d, 51 μm vs. 81 μm). To gain spatial and not just depth 
information about the released cargo compared to the NP delivery vehicle we further 
analyzed the LN Z-stacks by creating maximum intensity projections and then processing 
the images using custom ImageJ and MatLab scripts to obtain the distance between each 
fluorescent pixel within the LN and the LN boundary (Figure 5.4a-c). By looking at the 
relative spatial distribution of the single channel fluorescent pixels within the LN from 
either 3-Rhod released cargo or 647-NP (Figure 5.3d, lower right, blue and red) we found 
that the shallower distances from the LN boundary (Figure 5.3d, lower left, white dashed 
outline) were more biased for NP fluorescence (Figure 5.3e, blue) compared to the 
central, deeper areas of the LN which were biased more for the released 3-Rhod cargo 
(Figure 5.3e, red). 
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Figure 5.4: LN fluorescence spatial distribution. a) LN confocal images are 
converted to maximum intensity projections of all Z stacks. Images are separated 
from 2-channel overlaid into NP and 3-Rhod fluorescence images. b) Outline is 
drawn around single channel LN images. The custom ImageJ and Matlab program 
will measure the minimum distance (solid arrow) between each fluorescent pixel 
and the outline (dashed line). c) Composite graph of the difference in normalized 
pixel value for NP and Rhod from all LN in (A) vs. the distance from the capsule. 
5.3.3 OND-NP bias dLN-resident cellular biodistribution 
While the advantages of using a targeted delivery strategy for lymphatic uptake to 
improve LN accumulation include dose sparing and minimizing the potential for 
undesirable off-target effects and/or toxicities,[102] studies looking at the distribution of 
molecules within the LN support the concept that despite nanoformulations of an 
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intermediate nanoscale size being ideal for lymphatic uptake after injection in the 
periphery, small molecules have increased potential to travel deeply within the LN 
conduits and possibly within the cortex (Figure 5.5a).[84, 85] A controlled release 
strategy of co-formulated drug such as the multi-stage release strategies that have 
previously been used to improve intratumoral drug penetration,[103] might be utilized to 
differentially target LN-resident cells by exploiting LN physiology with larger drug 
delivery vehicles being primarily restricted by the subcapsular sinus, while the released 
small molecule cargo is free to penetrate the LN conduits that run deep into the cortex 




Figure 5.5: Cellular distribution of OND cargo within LN. a) Spatial distribution of 
soluble species within LN shows that large particulates (blue) are restricted by the 
subcapsular sinus (blue cells) from access to the LN cortex, while smaller antigen 
and molecules (red) efficiently enter the LN conduits and travel deep within the LN. 
b) Distribution of cells within the LN showing that the majority of cells, 
lymphocytes, are currently un-targetable by large particulate delivery vehicles 
which are restricted by the small number of LN barrier cells. c) Representative 
image of OND cargo (red) penetrating the central area of the LN greater than the 
SH-NP (blue), which remained shunted towards the LN capsule. White line, 500 μm. 
d) Peak distance for the penetration of SH-NP or OND cargo into the LN from the 
LN boundary. The large distance to which OND cargo is present from the LN 
boundary mirrors the representative image in (c). n=24 samples per group. e) 
Representative images staining the LN for CD3 and B220 (red, lymphocyte) vs. 
CD169, F4/80, lyve-1, and CD11c (green and blue, barrier cells) showing that the 
lymphocytes are located more centrally in the LN than the barrier cells. f) 
Breakdown of all LN cells for OND and SH-NP positivity showing that release of 
OND cargo, which penetrated deeper into the LN (d), afforded access to a much 
greater percent of the LN cells compared to free cargo or SH-NP. n=6 samples per 
group. ***p<0.005. g) Distribution of cells positive for OND cargo or SH-NP within 
the LN. Barrier cells show greater percent of NP+ for SH-NP delivery vehicle while 
Lymphocytes show greater percent for 3-Rhod when delivered by OND-NP. n=6 
samples per group. g) Representative flow cytometry for T and B cells showing 
dramatic increase in OND signal for OND-NP delivery compared to free Rhod 
delivery, while NP signal remained relatively low. i) Number of cells positive for 
OND compared to NP show that release of cargo dramatically increases the total 
number of cells positive for cargo. n=6 samples per group. j) Percent of cells positive 
for OND cargo compared to NP show that release of cargo dramatically increases 
the percent of cells positive for cargo. n=6 samples for all groups. Cells were gated 
as follows: B cells -B220+CD3-CD11b-; T cells – CD3+B220-; conventional dendritic 
cells (CDCs) – CD11c+B220-; plasmacytoid dendritic cells (PDCs) – CD11c+B220+; 
subcapsular sinus macrophages (SSM) – B220-CD3-CD11b+CD11c+CD169+F4/80-; 
medullary sinus macrophages (MSM) - B220-CD3-CD11b+CD11c+CD169+F4/80+; 
and medullary cord macrophages (MCM) - B220-CD3-CD11b+CD11c+CD169-
F4/80+. For all graphs the columns/points and error bars represent the mean + 
SEM. 
With our data demonstrating that release of cargo afforded some spatial and 
accumulation differences over permanently bound NP cargo (Figure 5.5c) we assessed 
the OND cargo and NP peak central fluorescence distance and found that OND cargo was 
much more centralized within the LN than NP (Figure 5.5d). When we compared these 
results to immunohistochemistry (IHC) stained slices of naïve LN looking for 
lymphocytes (CD3 and B220), APCs (CD11c), and barrier cells (CD169, F4/80, LYVE-
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1) (Figure 5.5e), we found that lymphocytes and APCs were concentrated in the deep 
central portions of the LN, whereas the barrier cells remained closer to the LN boundary 
(Figure 5.5e) demonstrating that the spatial distribution of cells of the adaptive immune 
system overlapped with the central distribution of released OND cargo hinting at greater 
access to these cells through cargo release.  
We next performed flow cytometry on LN-resident cells to see which cell types 
were targeted. Using both 647-NP and 3-Rhod as our model small molecule cargo we 
first assessed the total cellular uptake. Permanently bound cargo (647-NP), 3-Rhod mixed 
with 647-NP, and free 3-Rhod alone showed very little percent (<1%) of cells positive for 
cargo (Figure 5.5f). Contrastingly, rhodamine delivered on OND-NP, showed a 
dramatically increased cellular accumulation, reaching an average of nearly 40% of all 
dLN-resident cells (Figure 5.5f). Based on our analysis of the IHC slices of naïve LN we 
next assessed what cell types were responsible for this uptake and if release of cargo was 
affording differential access of cargo to different cell types. We found that 
immunotherapeutic cellular targets (T cells, B cells, and DCs) were strongly and 
primarily Rhod+NP- when delivered by OND-NP, while these cell types were also 
Rhod+NP- for the free and mixed groups, but at a much lower level (Figure 5.5g, 
Lymphocytes). Furthermore, we found that the barrier cells (CD169+ SSM, MCM, and 
MSM) were nearly 100% Rhod+ either as Rhod+NP- or Rhod+NP+ (Figure 5.5g, Barrier 
Cells). Interestingly, these barrier cells also were Rhod+ for the free, mixed, and 
permanent groups, but the results were not as strong as for the OND-NP (Figure 5.5g).  
We next wanted to delve deeper into our immunotherapeutic targets T, B, and 
DCs. Using flow cytometry we found that the rhodamine signal massively increased for 
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both T and B cells (Figure 5.5h, upper), while the NP signal for both of these groups 
remained relatively subdued (Figure 5.5h, lower) reconfirming the studies showing 
restricted access to lymphocytes by large particulates.[84, 85] We further quantified this 
change by looking at both the number of positive cells and percent positive by comparing 
OND-NP to NP formulation, which is the current state-of-the-art for LN delivery. We 
first found that the number of T, B, and DCs positive for cargo dramatically increased 
when the cargo was released via OND-NP with T cells going from hundreds to tens of 
thousands, B cells going from several thousand to the hundreds of thousands, and DCs 
going from hundreds to thousands (Figure 5.5i). Interestingly, cargo-positive macrophage 
numbers remained relatively unchanged by cargo release indicating that NP might 
already be delivered to this cell type with maximum efficiency (Figure 5.5i). When 
quantified as a percent positive we recorded nearly 10% of T cells, 60% of B cells, 50% 
of DCs, and 100% of macrophages being positive for cargo when released by OND-NP 
(Figure 5.5j), indicating that this system could have dramatic improvements on 
immunotherapeutic LN delivery.  
5.3.4 OND-CpG-NP immunotherapeutic tumor experiments 
With all of the data we had supporting the fact that OND-NP-mediated release of 
small molecule cargo afforded: 1) better accumulation of small molecule cargo within 
LN; 2) enhanced LN penetration; and 3) increased number and type of cells that are 
positive for cargo. We next sought to apply our OND-NP system to immunotherapy for 
cancer. The LN draining the local tumor interstitium has been shown to be an important 
immunotherapeutic target for tumors since it is bathed in tumor-derived antigen[115] and 
delivery of adjuvants has previously been shown to be effective in inducing pro-tumor 
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cytotoxic responses. Therefore, to test our OND-NP system we incorporated the TLR 
ligand 9 CpG oligonucleotide onto our 30 nm NP using an OND linker (Figure 5.6a), and 
tested the conjugation and release of OND-CpG from the PDS-NP over 72 h (Figure 
5.6b) and found that the release was unchanged with a half-life around 8 h (Figure 5.6c).  
 
Figure 5.6: Conjugation and release characterization of OND-CpG-NP. a) PDS-NP 
are thiol-activated and reacted with CpG-OND to create OND-CpG-NP. b) OND-
CpG-NP solution was placed in a 37°C water bath and aliquots were withdrawn at 
0, 24, and 72 h and run on a CL6B column in order to determine the percent of CpG 
that coeluted with NP. CpG was measured using GelRed staining and NP were 
measured using Iodine staining. c) Table of % of CpG for each species in (b).  
 108 
We next evaluated the efficacy of OND-CpG-NP delivery to the TDLN in treating 
both primary and LN-metastatic tumors. To this end, we implanted EL4 T cell lymphoma 
cells in the left shoulder dorsal skin of C57BL/6 mice; after primary tumor establishment 
and allowing for LN tumors to be formed, four days post implantation we intradermally 
injected 0.75µg of OND-CpG-NP, NP-disulfide linked CpG (PTO), free CpG, or PBS 
daily in the limb ipsilateral (i.l.) to the tumor for five days (Figure 5.7a). After 12 days 
OND-CpG-NP treatment of the i.l. limb resulted in reduced LN size compared to all other 
groups (Figure 5.7b,c). Furthermore, OND-CpG-NP treated LN were similar in size to 
that of non TDLN PBS mice (Figure 5.7b,c) indicating a potent anti-tumor immunity. To 
further support this claim, we also observed an abscopal effect on the primary tumor with 
OND-CpG-NP treatment of the TDLN resulting in slowing of tumor growth relative to 
control (Figure 5.7d), with the other CpG groups not resulting in any appreciable 
therapeutic effect.  
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Figure 5.7: In vivo CpG delivered from OND-NP dramatically reduces EL4 LN 
tumor size. a) EL4 dorsal skin tumor implantation diagram. 250K EL4 are 
implanted in the left dorsal skin of the mouse (white circle). The EL4 tumor cells 
will drain (dashed white arrow) to the TDLN (pink circles) The CpG solutions are 
injected intradermally in the mouse forearm, which drains (yellow dashed arrow) to 
the same TDLNs as the tumor. b) EL4 LN tumor size was reduced with CpG-OND-
NP compared to other treatment groups to levels not statistically different than non-
TDLN. n=5 per group. c) Representative pictures of LN shows that OND-CpG-NP 
treated LN are similar to non TDLN. d) OND-CpG-NP slows the growth of the 
primary tumor while other CpG groups do not. n=4-6 samples per group. n=5 per 
group. e) The number of total LN cells and cells of each subtype was substantially 
increased in the LN with CpG-OND-NP treatment. n=6 per group. f) The 
maturation of cDCs was statistically significantly increased for MHCII MID CD40 
MID in CpG-OND-NP treated LN compared to all other groups. For MHCII MID 
CD86 MID cells, CpG-OND-NP also increased the percentage of CD11c+, but not to 
a statistically significant amount. n=6 per group. For all graphs the columns/points 
and error bars represent the mean + SEM. 
We next performed in vivo tests to help elucidate the dramatic tumor reduction 
effect caused by delivery of CpG through OND-NP. We injected OND-CpG-NP, PTO-
CpG-NP, or free CpG into the forearms of mice and 24 h later analyzed the dLN by flow 
cytometry for the proliferation and maturation of the APCs. We found that when 
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administered via OND-NP the CpG caused a large increase in the total proliferation of 
LN-resident cells, nearly tripling the number of dLN-resident cells from between 1-2M to 
over 6M for OND-CpG-NP (Figure 5.7e). Furthermore, this increase in cell numbers 
within the LN-resident cells occurred strongly for all TLR9-positive cell types including 
B cells, plasmacytoid DCs (PDC), and conventional DCs (cDC) (Figure 5.7e). Delving 
further within the CD11c+ cDC population, which is primarily responsible for tumor 
antigen presentation from the conduits to T cells, we found that these cells were of a 
more mature phenotype as indicated by CD40 and CD86 expression with OND-CpG-NP 
showing greater expression compared to no change between saline and any other CpG 
group (Figure 5.7f). Since EL4 lymphoma cells do not express TLR9,[212, 213] these 
results combined with the tumor data point to a potent systemic immunotherapeutic 
response. 
5.4 Conclusion 
In summary, we described a versatile lymphatic-targeting NP system that is able 
to precisely tune the release profile of conjugated cargo, allowing the cargo to utilize its 
naturally enhanced diffusivity compared to the larger NP delivery vehicle. We showed 
that release of cargo from OND-NP increased collagen penetration and dramatically 
altered the spatial distribution within the LN achieving deeper penetration and access to 
the more centralized LN structures. This cargo spatial bias aligned with IHC staining 
showing that the NP restricted from centralized LN access would never be able to access 
the vast majority of LN-resident immune cells and that OND-NP released cargo could 
spatial target these cells. When we assessed if this spatial bias resulted in changes to 
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cellular accumulation and access we found hundreds of fold improvement in the ability to 
target deep LN-resident cells. 
Utilizing our enhanced adaptive immune cell access, we were able to conjugate 
the TLR9 ligand CpG to our OND-NP and demonstrated a substantial immunotherapeutic 
response against an EL4 lymphoma model shown by a dramatic reduction in LN tumor 
size compared to other CpG delivery strategies, and a slowing of the primary tumor 
growth. This therapeutic response most likely occurred through the proliferation and 
maturation lymphocytes within the treated LN, demonstrating a potent systemic anti-
tumor immune response.  
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CHAPTER 6. Concluding Remarks and Future Directions 
 
6.1 Conclusions 
Current drug delivery for the lymphatics and LNs seeks to overcome several 
barriers that result in inefficient targeting of the tissue’s anatomical location. First, the 
propensity of small molecule therapeutics to go to the blood following intradermal 
administration is overcome by formulation into larger drug delivery vehicles, which have 
blunted blood permeability and therefore result in greater lymphatic uptake efficiency. 
The second barrier is less appreciated and involves the barrier of the LN structure itself 
and the resulting regulation of molecular freedom within the LN. Because the LN, 
especially in the context of cancer – vis-a-vis the TDLN – has recently become a tissue 
target of interest, many drug delivery strategies solely focus on achieving LN 
accumulation without analysis of the more important aspect of cellular accumulation. 
Studies concerning the mechanisms of adaptive immune responses have shed light on 
these aspects, showing the size-based fate of lymph-borne soluble antigen and their 
access or lack thereof to the different cell types and compartments of the LN.  
Given the research into the microanatomical biodistribution of molecules based 
on size within the LN, we have designed biomaterials to harness endogenous LN 
regulating structures to achieve greater delivery of immunotherapeutic payload to the 
LN-resident cells. In the first aim we explored an endogenous mechanism to achieve 
release of payload, specifically NO, which has many functions on lymphatics and 
lymphocytes that have putative therapeutic potential. Our SNO-NP delivery vehicle not 
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only increased the amount of NO delivered to the LN via standard drug delivery 
principles, but also hinted at increased cellular access due to the proliferative response of 
the lymphocytes. In the second aim, we used an engineered linker to release our cargo in 
a time-based fashion similar to multi-stage delivery systems that have previously been 
used for tumor targeting, but have never been applied to LNs. We demonstrated that this 
release afforded increased penetration and cellular access of the cargo, whereas the larger 
NP delivery vehicle remained blunted from LN penetration. We applied this novel 
delivery system to the adjuvant, CpG, and showed improved APC maturation as well as 
immunotherapeutic response against LN and primary lymphoma tumor. 
6.2 Contributions to the Field 
The overall impact of this work was to address multiple aspects of delivery to LN 
by recognizing that LN drug delivery should not only concern itself with the tissue target, 
but importantly with the cellular targets within that tissue. The structure of the lymphatic 
tissues controls access to the cells involved in the adaptive immune response, and the 
spatial, temporal, and cellular constraints cannot be accurately addressed by the broad 
metric of “accumulation” within the target tissue that is achieved by current drug delivery 
formulation. The main contribution of this work is the fact that we have created the first 
multi-stage drug delivery systems to overcome both the lymphatic uptake and LN 
structural delivery barriers to achieve enhanced delivery to cells within the LN. 
6.2.1 SNO-NP for enhanced NO delivery to lymphatics/LN 
Chapters 3 and 4 of this work detailed the design of a drug delivery vehicle for the 
transport of NO to deep tissues such as the lymphatics and LN. Our design had several 
unique advantages over current NO donors in that: 1) the unique size of the SNO-NP 
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significantly enhanced lymphatic targeting activity; 2) we used an endogenous NO 
conjugation and release chemistry that was physiologically compatible and degradable, 
and biologically active; and 3) the system resulted in biological potency with 
transnitrosation to lymph-borne thiols and cytotoxicty against lymph-resident parasites.  
This work, to the best of our knowledge, was the first SNO-delivery NP system 
designed for both the targeting of LNs and LN-resident cells. This work will help the 
field by demonstrating that NO can be efficiently delivered to the lymphatics and LN 
cells. Additionally, this work demonstrates the ability to achieve controlled delivery of 
NO, a highly reactive molecule, and proposes a novel therapeutic for the treatment of 
lymphatic-related diseases including lymphatic-resident filarial worms, to which there is 
currently no targeted cure available.  
6.2.2 Multi-stage OND linker for enhanced LN cellular access 
Chapter 5 of this work explored the use of an engineered, as opposed to an 
endogenous (in the case of SNO-NP), release mechanism for achieving enhanced cellular 
delivery of cargo to LN-resident cells. Our system is one-of-a-kind and improved upon 
the existing drug delivery systems for LN by: 1) employing a time-sensitive release linker 
that is insensitive to pH, salt, and enzyme presence to achieve remarkably precise release 
kinetics of conjugated cargo; 2) combining the lymphatic uptake efficiency of a large NP 
drug delivery vehicle with the improved diffusivity and LN-structure access of small 
lymph-borne small molecules to achieve unparalleled LN-resident cellular access; and 3) 
establishing the importance of cellular access for the generation of adaptive immune 
responses against cancer.  
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This work, to the best of our knowledge, is the first “multi-stage” drug delivery 
system for LN targeting. While there have been a few examples of multi-stage systems 
for improving the penetration of solid tumors following carrier extravasation into the 
tumor, there have been no systems exploiting the LN reticular structure by which small 
antigens are able to access deeper LN cortical cells. Furthermore, this work for the first 
time proposes that enhancing access to LN-resident cells can improve adaptive immune 
responses against cancer and should be necessary criteria for any LN drug delivery 
systems. 
6.3 Future Directions 
The future directions of my work should seek to further the innovations made in 
this thesis on lymphatic and LN targeting. No longer relying on the metric of tissue 
accumulation, future work should always seek to understand the cellular impact of drug 
delivery to thesis tissues, be it the lymphatic endothelial cells (LECs) or lymphocytes of 
the lymphatics and LN. Regarding the lymphatics I would like to see the SNO-NP system 
being used to probe the transport properties of the lymphatics under the influence of 
differential concentrations of NO. Additionally leveraging the lymphatic targeting of the 
SNO-NP, I would like to see a future project exploring the in vivo cytotoxicity of 
lymphatic-resident filarial worms to SNO-NP and a characterization of the immune 
response the results from this treatment. Both of these future projects will have major 
implications for lymphatic-related diseases that affect millions worldwide. Within the LN 
I would like to see future projects aimed at expanding the types of molecules delivered 
via OND-NP. These molecules could be therapeutic in the cases of chemotherapy where 
delivery of a high concentration of small molecule drug is used to kill LN-resident tumor 
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cells or they could be used for basic science where molecules such as lymphocyte homing 
chemokines or selectin inhibitors are delivered in order to probe basic questions about 
adaptive immune generation between APCs and T cells. Projects such as these would 
have implications in furthering our understanding of LN physiology as well as adaptive 
immune mechanisms and will contribute to improving functional outcomes such as 
vaccine responses and anti-tumor immunity.  
6.3.1 SNO-NP for use in understanding the role that NO plays in lymphatic function 
Future work using this system should aim to characterize the extra- and intra-
lymphatic NO levels required to impair lymphatic transport activity with the long-term 
goal being to establish a robust, biocompatible NP technology for the tuning of NO levels 
and lymphatic function in vivo. Currently, there are no reliable ways of precisely 
delivering NO intraluminaly to the lymphatics in order to assess its effect on pumping 
function. In previous work NO is applied externally to the tissue and then an unknown 
concentration over an unknown time scale reacts with lymphatic smooth muscle cells 
altering lymphatic pumping. The SNO-NP platform could be used to precisely deliver a 
known concentration of NO to the lymphatics with known release kinetics in order to 
understand exactly how the concentration of NO generated by the lymphatic endothelial 
cells affects lymphatic function. This work outlines the use of both the mouse forearm 
lymphatic model as well as the rat tail lymphatic model for assessment using different 
techniques on the treatment of lymphatics with NO. The importance of this work could 
extend to lymph edema, which is characterized by aberrant lymphatic pumping, as well 
as to inflammatory diseases of the lymphatics including obesity and parasitic infection.  
6.3.2 SNO-NP as a lymphatic/LN therapeutic 
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Future work for SNO-NP as a lymphatic/LN therapeutic should seek to exploit 
NO’s therapeutic potential in producing cytotoxicity against lymphatic parasites, 
reducing lymphocyte proliferation, serving as a chemotherapy sensitizer for lymphoma, 
or producing chemotherapeutic-resistance to DCs. All of these diseases are uniquely 
addressable by the SNO-NP system as no other method of NO delivery can target both 
the lymphatics and LN with precise NO delivery. The work detailed in this thesis should 
lay the foundation for assessing these therapeutic challenges by using a Jird or 
immunocompromised mouse model to assess in vivo cytotoxicy against lymphatic filarial 
worms, using the mouse forearm model in Chapter 4 to assess effects of NO on LN-
resident T cells and DCs, and using the mouse tumor model in Chapter 5 to assess the 
effects of NO on chemotherapy resistance of DCs in tumor treatment. 
6.3.3 OND-NP for enhanced therapeutic and basic science exploration of the adaptive 
immune response 
Future work for the OND-NP system should aim at exploring the delivery of other 
treatments to the LN including small molecule chemotherapies as well as using this 
system to probe basic science questions by delivering integrin inhibitors to alter T cell 
immunological synapse recognition with APCs. We have done preliminary studies using 
the topoisomerase-1 inhibitor, irinotecan, which we were able to efficiently conjugate to 
the NP using OND chemistry.[214] We assessed the potency of this drug in vitro against 
endogenous splenocytes and exogenous EL4 lymphoma cells, and further assessed the in 
vivo effect on LN-resident cells in the dLN to OND-irinotecan. This work could expand 
upon the tumor immunology work in Chapter 5 by doing a combination therapy to 
potentiate the adjuvant effects of CpG delivered through OND by producing more 
antigen in the LN by killing LN tumor cells.  
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Alternatively, the use of the OND-NP platform for the use in LN basic science has 
many promising opportunities. In order to elicit potent cytotoxic T cell responses APC 
activation of T cells is required. The major histocompatibilty complex (MHC) on the 
APC interacts with the T cell receptor (TCR) on the T cell in what is called the 
immunological synapse.[111] The MHC has been found to be surround by intracellular 
adhesion molecules (ICAM) while the TCR is surrounded by leukocyte functional 
antigen (LFA-1). The interaction between ICAM and LFA-1 is thought to stabilize the 
weak MHC and TCR interaction and allow for improved signalling. By delivering an 
inhibitor of this synapse, aspects of the adaptive immune response in vivo and in situ in 
the LN could be probed.[215] OND-NP are uniquely suited to deliver this small molecule 
inhibitor through either direct access to the T cells or by targeting conduit lining DCs that 
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